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Abstract  
 
Huntington's disease (HD) is caused by an expanded polyglutamine (polyQ) tract in 
the huntingtin (Htt) protein. The polyQ expansion increases the propensity of Htt to aggregate 
and accumulate, and manipulations that mitigate protein misfolding or facilitate the clearance 
of misfolded proteins are predicted to slow disease progression based on studies in HD 
models. αB-crystallin (αBc) or HspB5 is a well-characterized member of the small heat shock 
protein (sHsp) family that reduces mutant Htt (mHtt) aggregation and toxicity in vitro and in 
Drosophila models of HD. Here, we determined if overexpressing or diminishing αBc levels 
in vivo modulates aggregation and the onset and progression of disease in a full-length mouse 
model of HD known as the BACHD mice. Expression of sHsps in neurodegenerative disease 
predominantly occurs in non-neuronal cells, and in the brain, αBc is mainly found in 
astrocytes and oligodendrocytes. In Chapter 3, we show that directed αBc overexpression in 
astrocytes improves motor performance in rotarod and balance beam tests, and improves 
cognitive function in the BACHD mice. Improvement in behavioral deficits correlated with 
mitigation of neuropathological features commonly observed in HD. Interestingly, astrocytic 
αBc overexpression was neuroprotective against neuronal cell loss in BACHD brains, 
suggesting αBc might act in a non-cell-autonomous manner. At the protein level, αBc 
decreased the levels of soluble mHtt and decreased the size of mHtt inclusions in BACHD 
brain. These results support a model in which elevating astrocytic αBc confers 
neuroprotection through a putative non-cell-autonomous pathway that modulates mHtt 
aggregation and protein levels. 
In Chapter 4, we attempted to elucidate the non-autonomous mechanism by which 
overexpressing astrocytic αBc confers neuroprotection in the progression of the disease of the 
BACHD mice. Several essential cellular pathways are impaired in neurological disorders such 
as HD. Among others, activation of caspase-3 pathways as well as formation of carbonyl 
species are oxidative stress hallmarks of HD pathology, and αBc has been reported to play a 
role in these mechanisms. Our studies, looking at mRNA and protein levels from BACHD 
mice as well as from primary cells (astrocytic and neuronal), found no significant differences 
in caspase-3 activation, and in expression of several HD markers, e.g., Glucose transporter 1 
(Glut1), dopamine receptor 1 (DR1) and dopamine receptor 2 (DR2), brain-derived 
	  	   ix	  
neurotrophic factor (BDNF), in this disease context. Despite not finding a significant 
difference, when looking at the formation of protein carbonyls (derived from oxidative stress), 
we found a small trend towards a decrease of the levels of these species when αBc was over-
expressed in astrocytes, both in brains and primary cultures of BACHD. These data may 
support the potential antioxidant effect of αBc in the context of HD pathology. 
In Chapter 5, we hypothesized that αBc deficiency would accelerate HD disease 
severity and progression, as previously observed in a mouse model of Alzheimer’s Disease 
(AD). We tested this hypothesis by crossing mice null for αBc (and HspB2) to BACHD mice 
and monitoring behavioral and neuropathological symptoms of HD during disease 
progression. Our study showed that genetic deficiency of αBc (and HspB2) did not aggravate 
disease progression. 
Taken together, the results presented in this thesis provide novel insight into the role 
of αBc and its function on essential cellular pathways in the context of HD. This work also 
supports the emerging significance of non-neuronal cells in chronic diseases such as HD 
suggesting adaptive and differential responses that might contribute to and/or provide a route 
to therapy of distinct aspects of neurodegeneration. Ultimately, this knowledge aims to 
promote and highlight the impact and role of sHsps, specifically αBc, in HD and related 
disorders in order to help the development of promising therapeutics for these devastating 
diseases. 
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 Resumo 
 
A doença de Huntington (HD) é causada por uma expansão de poliglutamina (polyQ) 
na proteína huntingtina (Htt). A expansão de polyQ aumenta a propensão da Htt para se 
agregar e acumular, e manipulações que mitiguem a mal-formação proteica ou que facilitem a 
degradação destas proteínas mal-conformadas são capazes de abrandar a progressão da 
doença em modelos de HD. αB-cristalina (αBc) ou HspB5 é uma proteína bem caracterizada 
membro da família das “small heat shock protein” (sHsp) que reduz a agregação e toxicidade 
da huntingtina mutante (mHtt) em estudos in vitro e em modelos Drosophila de HD. Aqui, 
determinámos se a sobre-expressão ou diminuição dos níveis da αBc in vivo foi capaz de 
modelar a agregação e atrasar o aparecimento e a progressão da doença num modelo de longo 
comprimento genético de HD, os ratinhos BACHD. A expressão de sHsps em doenças 
neurodegenerativas ocorre predominantemente em células não-neuronais, e no cérebro, a αBc 
é principalmente encontrada em astrócitos e oligodendrócitos. No capítulo 3, demonstrámos 
que a sobre-expressão da αBc dirigida em astrócitos melhorou a performance motora nos 
testes de Rotarod e Balancim “Balance Beam” e melhorou a função cognitiva dos ratinhos 
BACHD. A melhora dos déficits de comportamento esteve relacionado com a mitigação de 
características neuropatológicas muito comuns observadas em HD. Interessantemente, a 
sobre-expressão astrocítica da αBc foi neuroprotectora contra a perda neuronal nos cérebros 
dos BACHD, sugerindo que αBc talvez esteja a actuar de uma forma celular não autónoma. 
Ao nível proteico, a αBc diminuíu os níveis de mHtt solúvel e diminuíu o tamanho das 
inclusoes de mHtt nos cérebros dos BACHD. Estes resultados apoiam um modelo no qual 
elevar a αBc astrocítica confere neuroprotecção através de um potencial mecanismo celular 
não-autónomo que modela os agregados e os níveis proteicos solúveis da mHtt. 
No capítulo 4, tentámos elucidar o mecanismo celular não autónomo pelo qual a 
sobre-exressão da αBc confere neuroprotecção na progressão da doença dos ratinhos 
BACHD. Vários mecanismos celulares essenciais estão debilitados em doenças neurológicas 
como a HD. Entre muitos, a activação das vias da caspase-3, transporte e sinalização de 
glutamato e stress oxidativo são marcas moleculares comuns na patologia da HD, e a αBc tem 
um papel nestes mecanismos. Os nossos estudos baseados no mRNA e níveis proteicos dos 
BACHD e também em células primárias (astrócitos e neurónios), não mostraram uma 
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diferença significativa na activação da caspase-3, e na expressão do transportador-1 do 
glutamato neste contexto. No entanto, quando investigámos a formação de grupos proteicos 
carbonilo (derivados do stresse oxidativo), encontrámos uma pequena tendência para a 
diminuicão destas espécies de carbonil na presença da sobre-expressão astrocítica da αBc, 
tanto nos cérebros como nas culturas primárias dos BACHD. Estes dados apoiam o potencial 
efeito antioxidante da αBc no contexto da patologia de HD.   
 No capítulo 5, hipotetizámos que a deficiência em αBc iria acelerar a severidade e 
progressão da doença de HD, como tinha sido previamente observado num modelo de 
Alzheimer. Nós testámos esta hipótese, cruzando animais nulos para αBc (e para HspB2) com 
os ratinhos BACHD, e monitorizando sintomas comportamentais e neuropatológicos de HD 
durante a progressão da doença. O nosso estudo mostrou que a eliminação genética de αBc 
não agravou a progressão da doença de HD. Em suma, os resultados apresentados nesta tese 
fornecem uma nova perspectiva no papel da αBc e da sua função em mecanismos celulares 
essenciais no contexto de HD. Este trabalho também apoia o crescente papel e significado de 
células neuronais em doenças neurológicas como a HD, sugerindo respostas adaptativas e 
diferenciadas que podem contribuír e/ou providenciar um caminho terapêutico de aspectos 
distintos de neurodegeneração. Por último, este conhecimento tem como objectivos, promover 
e realçar o impacto das sHsps, especialmente a αBc em HD e outras doenças relacionadas 
para ajudar a desenvolver terapêuticas promissoras para estas doenças devastadoras.  
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Chapter 1. General Introduction 
 
1. Huntington’s Disease 
 
1.1.  Historical Background 
 
Huntington’s disease (HD), originally called simply 'chorea' or ‘hereditary chorea’, 
has been recognized as a disorder since the Middle Age. Nevertheless, it was just in 1872 that 
George Huntington, a young physician from Connecticut, published the first accurate 
description of the disease (1). 
This neurological disease was described as dominantly inherited, affecting several 
family generations, and characterized by an excessive dance–like motor movements (the 
major motor abnormality occurring in HD), neuropsychological deficits, including cognitive 
and psychiatric impairment, and gradual deterioration that would ultimately lead to death (2).   
In 1983, a study conducted by a consortium of researchers – The US-Venezuela 
Huntington's Disease Collaborative Research Project – took place in the Lake Maracaibo 
region of Venezuela. This region was known for its high density of HD cases and significant 
consanguinity, linked a polymorphic DNA marker genetically to HD (3). More than a century 
passed since the first description of HD until the underlying genetic mutation was identified 
(4). Shortly, the polymorphic DNA marker consists of an abnormal expansion of a CAG 
trinucleotide repeat sequence in the coding region of the HD IT15 (Interesting Transcript 15) 
or HTT gene, on the short arm of chromosome 4 (4p16.3). The CAG repeat encodes a 
polymorphic stretch of glutamines (Q) within the N-terminal region of a high molecular 
weight protein, with approximately 3144 amino acids (~348 kDa), known as Huntingtin (Htt) 
(5). Since identification of the disease-causing gene, several approaches and a number of 
genetically modified cellular and animal models were developed to enable the study of the 
molecular underpinnings of HD, to possibly bring us closer to identify possible therapeutic 
strategies for this devastating disease. The first HD mouse model, called R6/2, was created in 
1996 (6) and a year later, accumulation of mutant Htt (mHtt) in intranuclear inclusions was 
discovered in the brain of this HD mouse model and related to the pathogenic mechanism in 
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HD (7). Similar neuropathological features were also found in the brains of HD patients (8). 
Despite the intense effort on HD research since its first discovery, no clinical interventions 
tested in cellular and animal models to date have delayed the disease progression in humans. 
However, these models provide an invaluable tool for both investigating the underlying 
pathogenic processes and developing new effective therapies. 
The details of the genetic aspects of HD and Htt - inclusion bodies formation will be 
described throughout this Chapter as well as some of the most promising therapeutic 
approaches for HD.  
 
1.2. Epidemiology 
 
The prevalence of HD, incorporating both genetic and clinical diagnostic studies, is 
approximately 10-13 in 100,000 people worldwide (9, 10), but it can vary to a great extent 
and can affect 700 per 100,000 individuals in some secluded regions of Venezuela (11). The 
age of onset is typically between 35 and 50 years old, however 15% of the cases can occur 
before 20 years old, called juvenile HD cases. The life expectancy of this devastating and 
progressive disease is typically 15-20 years from onset of symptoms till death (12).  
 
1.3. The disease: Clinical presentation  
 
HD is typically characterized by movement impairment (Chorea), cognitive 
dysfunction and decline and psychiatric disorder (13, 14). Chorea is the most common and 
aggressive manifestation of HD. It consists of involuntary, abnormal and irregular movements 
(hyperkinetic movements) that can affect most of the body, in particular the limbs, trunk and 
face (15). As the disease progresses, chorea often stabilizes and bradykinesia and rigidity start 
taking place, which is a very common feature in other neurodegenerative disorders such as 
Parkinson’s disease (PD) (16). Individuals in the last stages of HD suffer from gait 
disturbances which compromises their mobility, leading to falls (17). In the very last stage of 
the disease patients are not able to swallow and ultimately they are incapable of eating and 
also breathing (15, 18). Regarding cognitive dysfunction in HD, dementia is a common 
feature in the majority of the cases, varying from the designated subcortical dementia in 
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which individuals are not able to learn new motor skills and their visuospatial memory is also 
affected to a very broad of cognitive decline (13, 19). Lastly, the psychiatric disturbances in 
HD are extremely diverse, but the most typical in patients are irritability, apathy, anxiety, 
depression and impulsivity (13). HD patients also commonly suffer from progressive weight 
loss, alterations in sexual behavior, and disturbances in the wake-sleep cycle that occur very 
early in the course of the disease and may partly be explained by hypothalamic dysfunction 
(20). Suicide is also prevalent among HD patients (21, 22). 
 
1.4. Genetic Factors and neuropathology of HD  
 
As previously mentioned, HD is a devastating autosomal-dominant neurodegenerative 
disease caused by an abnormal expansion of the CAG triplet in the exon1 of the IT15 gene, 
which encodes a polyglutamine (polyQ) segment in the Htt protein (5, 14).  
Unaffected alleles have CAG repeat size ranging from 10 to 35. With a median size of 
18, the most common alleles in all populations contain repeats of 15-20 CAGs (15). HD-
causing alleles are classified as: 1) Reduced- penetrance HD-causing alleles with 36-39 CAG 
repeats. An individual with an allele in this range is at risk for HD but may not develop 
symptoms. 2) Full-penetrance HD-causing alleles with 40 or more CAG repeats. Alleles of 
this size are associated with development of HD with great certainty (3). Individuals with 
adult-onset HD usually have a CAG expansion from 40 to 55. In that range, ~50-70% of age 
of symptom onset appears to be explained by the length of the polyQ stretch, whereas the 
remaining variance is plausible to occur by other modifying genes and environmental factors 
(23–25). In longer polyQ stretches, the length of the polyQ stretch explains a greater 
proportion of age of symptom onset. Like other polyQ disorders, there is an inverse 
correlation between the length of CAG repeats and the age of onset. Thus, the longer the CAG 
stretch, the earlier symptoms typically appear (Figure 1). HD juvenile onset cases have CAG 
expansions greater than 60 that are often inherited from the father (paternal transmission) (3, 
26).  
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Figure 1. The role of the CAG 
expansion in IT15 on HD 
pathogenesis. (A) Correlation of HD 
CAG-repeat length with age at onset. 
Best-fit curves for age at neurological 
onset (red) and duration of disease 
from onset to death (blue), plotted 
against CAG- repeat length for the 
expanded mutant allele from HD 
patients. Age at onset is strongly 
correlated with the CAG-repeat length 
(r2 ¼ 0.54; p < 0.001), and duration of 
disease shows no correlation with the 
CAG-repeat length, suggesting that, 
after onset of HD, factors independent 
of the original trigger of pathogenesis 
determine the rate of progression. 
Adapted with permission from (5). 
 
Although HD pathology has been observed in peripheral tissues (27) like other polyQ 
disorders, HD is predominantly a central nervous system (CNS) disorder, characterized by 
cell loss and atrophy (28), classified in five grades (0–4) designated in ascending order of 
severity (7, 29). 
Within the brain, atrophy of the striatum (the largest component of the basal ganglia 
system) is the most prominent (17) (Figure 2), which primarily include a selective 
degeneration of medium spiny neurons (MSNs) (which represent about 96% of striatal 
neurons, and receive synaptic input primarily from the cortex) in the caudate nucleus and 
putamen, while aspiny interneurons (which represent around 2% of the striatal neurons) of the 
striatum are generally spared (30). Counts of neurons in the caudate nucleus revealed that 
50% are lost in grade 1 and that 95% are lost in grade 4 (29).  
Nevertheless, gradual MSN’s degeneration in the caudate nucleus and putamen 
appears to be distinctive.  At early stages of HD, striato-globus pallidus (GP) internal 
segments (GPi) medium spiny projection neurons (which express substance P/gamma-
aminobutyric acid (GABA) and projects to and inhibit GPi resulting in thalamus disinhibition 
and subsequent excitation of upper motor neurons in the motor areas of the cortex, which 
increase movement - direct pathway) are relatively spared. In contrast, striato-GP external 
segments (GPe) (which express enkephalins and projects to and inhibit GPe resulting in 
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subthalamic nucleus inhibition and consequent less inhibition of substantia nigra (SN) pars 
reticulata (SNr) and GPi which inhibits thalamus resulting in the inhibition of upper motor 
neurons; thus decreasing movement - indirect pathway) and striato-SNr (which express 
substance P/GABA and projects to and inhibit SNr - direct pathway) medium spiny projection 
neurons degenerate (31); loss of striato-GPe neurons was also demonstrated in 
presymptomatic HD (32). The early and relatively selective loss of striato-GPe and striato-
SNr neurons was suggested to be a plausible explanation for the chorea and oculomotor 
abnormalities that are prominent clinical features of early HD (33). However, in later stages 
of adult HD, both populations of striatal projection neurons are affected, with concomitant 
loss of markers of the direct pathway (substance P/GABA-containing neurons), including 
dopamine D1 receptors and substance P (31, 34). In addition, in juvenile cases of HD, 
degeneration of both direct and indirect pathway striatal neurons was observed (34). Thus, the 
degeneration of both the direct and indirect pathways was suggested to be functionally 
correlated with bradykinetic rigid phenotype observed in late stage and juvenile HD patients 
(34). Also, within the spared aspiny interneurons in HD there appears to be a differential level 
of vulnerability (35). In addition, non-striatal brain regions can also be affected, particularly 
in latter stages of the disease, and can include the SN, hippocampus, and mostly various 
regions of the cortex (36). Pyramidal neurons of deeper cortical layers appear to be more 
affected in HD, which seem to be correlated with dementia and personality changes in HD 
patients (17).   
As previously discussed, brain atrophy and degeneration with marked neuronal cell 
loss in the regions mentioned above, putamen and caudate nucleus as well as cortex can occur 
before specific or severe motor symptoms appear in HD - asymptomatic patients – this period 
is defined by prodromal stage (Figure 2). At this point, affected patients can still perform 
usual functions although distress and discomfort may be felt (17). 
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Figure 2. Atrophy in prodromal HD shown using 7T MRI. Bilateral atrophy of the caudate and 
putamen, and a concomitant increase in size of the fluid-filled lateral ventricle, is observed in the gene 
carrier compared with the control. This prodromal participant has only subtle signs and symptoms that 
are insufficient for diagnosing manifest HD. There are also subtle changes in the cortical grey matter 
and overall atrophy of subcortical white matter (26). 
 
The reason why there is selective brain degeneration in HD remains unclear. However, 
it may be due to the role and importance of the Htt protein might have in the brain. The Htt 
polyQ tract begins at the 18 amino acid and is followed by a proline rich sequence (polyP) 
composed by 38 amino acids, which is considered to be important in Htt solubility (37). The 
first 17 amino acids of Htt are important for nuclear shuttling since they interact with TPR 
(translocated promoter region), a protein of the nuclear pore that actively exports proteins 
from the nucleus. Htt nuclear accumulation was observed when the first 17 amino acids were 
eliminated (38). Htt also contains multiple regions of so-called HEAT (Huntingtin, Elongation 
factor 3, a subunit of protein phosphatase 2ª nd the lipid kinase TOR) repeats, a sequence of 
~40 amino acids named after the first four proteins in which it was discovered (39, 40) 
(Figure 3). Although the exact function of HEAT repeats is still unclear, studies have 
suggested that these domains play a role in a variety of interactions between proteins, 
including transportation in the cytoplasm and nucleus, microtubule dynamics and 
chromosome segregation (39). 
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Figure 3. Structure of 
the Htt full-length 
protein (A) and of the 
N-terminal exon 1 of 
the gene (B). Panel (A) 
indicates the position of 
the three clusters of 
HEAT repeats, the 
caspase (black) and 
calpain (red) cleavage 
sites and some of the 
post-translational 
modification sites along 
Htt protein (C214  
palmitoylation, S421, 
S434 phosphorylation, K444 acetylation). Panel (B) shows the N-terminal product of the exon 1 of the 
Htt gene, with the 17aa N-terminal tail (green) and the post-translational modifications reported to 
occur on the indicated residues (T3, S13, S16 phosphorylation; K6, K9, K15 ubiquitination and/or 
SUMOylation); Q(n) indicates the polyglutamine tract (red) and the upper insert shows the correlation 
between polyQ size and HD severity; the polyproline region downstream polyQ stretch is indicated in 
purple (41). 
 
Htt mRNA and protein are ubiquitously expressed throughout development and in 
adulthood, in a variety of cells and peripheral tissues, and homogenously in the brain where it 
is higher expressed (8, 42), with a predominance of neuronal over glial expression (43–45). In 
the brain, Htt mRNA was detected in both grey and white matters (lowest expression levels), 
and the highest expression levels of Htt were found in the cortex (with differential expression 
between cortical layers), hippocampus, SN and cerebellum, followed by the striatum (43, 45). 
There are no differences in the distribution and levels of Htt mRNA between symptomatic 
HD patients and control individuals, except in the striatum where the intensity of labeling 
seems significantly reduced (42). However, presymptomatic HD brains revealed a striatal 
expression similar to controls and surviving striatal neurons in more advanced HD had an 
expression of Htt mRNA within normal limits. Therefore, HD brain selective degeneration 
does not seem to result from altered Htt mRNA expression (43). Wild-type (WT) Htt protein 
within neurons can be found mainly in the cytoplasm, but also in neurites and synapses. WT 
Htt can be associated with various organelles and structures, such as microtubules, plasma 
membrane, endosomal and endoplasmic compartments, clathrin-coated vesicles and 
mitochondria (46–48). Although mostly located in the cytoplasm, Htt is also detected in the 
nucleus (47). Due to its subcellular localization Htt interacts with numerous proteins involved 
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in gene expression, intracellular transport, signaling and metabolism, axonal trafficking of 
vesicles, transcriptional regulation and it also plays important functions in apoptosis and 
embryonic development (14, 49, 50). WT Htt is involved in embryonic development, since 
homozygous HTT locus knockout mice are lethally affected at early embryonic development 
stages (51–53). In contrast, the presence of one fully functional allele (at least 50% Htt 
expression) is compatible with life in humans and HD is not caused by a simple loss of 
function of the HTT gene (54). In fact, patients with Wolf-Hirschhorn syndrome, that have a 
partial deletion of chromosome 4 that comprises the CAG triplet repeats region and therefore 
contain only one copy of the HTT gene, are born and do not develop HD (3). WT Htt has an 
anti-apoptotic function in a gene and protein-dependent manner (55). In addition, WT Htt acts 
downstream mitochondrial cytochrome c release (a protein at the mitochondrial inter-
membrane space that when released from mitochondria can bind to caspases to activate the 
cell death process), preventing the activation of both caspase-3 (56) and caspase-9 (57). Also, 
WT Htt physically interacts with active caspase-3 and inhibits its activity (58). Furthermore, 
Htt has been suggested to have a role in transcriptional regulation. For example, Htt was 
shown to regulate the genetic transcription of brain-derived neurotrophic factor protein 
(BDNF), a signaling neurotrophin essential for striatal neuronal survival and for the activity 
of cortico-striatal synapses, by binding and trapping in the cytoplasm (inhibit) the BDNF 
transcriptional repressor REST/NRSF (RE-1 silencing transcription factor/neuron- restrictive 
silencer factor) (14, 59–61). Apparently, WT Htt facilitates a de-repression of BDNF 
transcription but polyQ-expanded Htt does not (60).  Thus, several studies have implicated 
that a reduction of BDNF at the transcriptional level is an important contributor to HD 
pathogenesis (60, 62).  
In the disease context, the Htt protein with an expanded and abnormal polyQ, now 
denominated mutant Htt (mHtt) becomes aberrant and toxic that leads to neurodegeneration 
(6, 26). At the cellular level, HD neuropathology is characterized by the presence of neuritic, 
cytoplasmic and nuclear inclusions of mHtt (7, 8). mHtt accumulation and toxicity are 
associated with neuropathological damage characterized by brain atrophy and neuronal cell 
death, even at prodromal stages (Figure 2). How this polyQ-expanded mHtt causes selective 
and progressive dysfunction and neurodegeneration remains unclear.  HD is one of at least 
nine genetic diseases caused by an abnormal expansion of a polyQ stretch, highlighting the 
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toxicity of polyQ-mediated protein misfolding in disease pathogenesis (54). However, 
increasing evidence points to the fundamental role that host protein context plays in 
pathogenesis. Expansion of its polyQ stretch beyond 36 repeats causes the protein to misfold 
and confers a toxic gain of function (GOF) (63). However, there is also evidence to support a 
contribution to disease pathogenesis from a loss of function of the WT allele (54).  While a 
GOF is consistent with the autosomal dominant inheritance, there is also evidence to support a 
contribution to pathogenesis from loss of function (LOF) of the WT allele (14, 54).  mHtt 
appears to have at least certain properties of WT Htt. In fact, mHtt can rescue the embryonic 
lethal phenotype seen in Htt-null knockout mice (64, 65). However, it is still not clear if 
neuronal cytotoxicity in HD is due to a LOF or GOF of Htt or actually both. Additionally, WT 
Htt has been implicated in a multitude of other cellular processes, including intracellular 
signaling, metabolism, gene expression, and intracellular transport, but its precise native 
function is still unknown (20, 21). Post-translational modifications (PTMs), in particular, 
greatly influence the toxicity of several different disease-associated polyQ proteins, including 
Htt (66). For instance, 4 several PTMs localized to the N-terminal 17 amino acids of Htt can 
modulate its toxicity (37, 67, 68). These residues, immediately preceding the polyQ stretch, 
are well positioned to alter the expansion’s propensity to cause protein misfolding via both 
direct and indirect means. However, other Htt PTMs farther away from the polyQ repeat 
region by primary sequence also have been reported to modify mHtt toxicity (49, 69). 
The proteolytic cleavage of mHtt into N-terminal fragments containing the polyQ 
stretch and their subsequent translocation to the nucleus and formation of intranuclear 
aggregates (8, 70) is an hallmark of the disease detected in post-mortem HD human brains. 
The aggregates can be found before the onset of the first symptoms (7), and the rate of 
aggregate formation was shown to correlate with the length of the polyQ repeat (71, 72). 
However, the toxicity of mHtt nuclear inclusions remains controversial, since their formation 
is correlated with disease progression, but it is not directly linked with neuronal degeneration 
as initially thought. In fact, several cellular studies, including many from our laboratory, have 
demonstrated that large mHtt inclusions can be protective against mHtt-induced toxicity and 
increase cell survival (8, 73, 74). Interestingly, exposure of mHtt-transfected striatal neurons 
to conditions in which nuclear localization of mHtt was blocked and consequently, 
suppressing its ability to form intranuclear inclusions, resulted in increased cell death, 
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suggesting that the formation of intranuclear inclusions might reflect a cellular mechanism to 
protect against mHtt-induced cell death (74). On the other hand, the decrease of proteolytic 
cleavage of mHtt reduced its toxicity and slowed disease progression (75, 76). In addition, 
expression of smaller N-terminal mHtt fragments resulted in increased toxicity in cultured 
cells (77) and transgenic animals (8, 78, 79), when compared to the full-length mHtt 
expression with the same polyQ expansion. These findings suggested that the susceptibility to 
neuronal death is greater with decreased protein length and increased polyQ size. Therefore, 
several HD models have been generated to mimic the neuropathological features that occur in 
humans. These models express only a fragment or a full-length (fl) mHtt to study the cellular 
and molecular mechanisms of mHtt-induce neurodegeneration.  
 
1.5. HD models  
 
A wide variety of species, including the invertebrate worm (Caenorhabditis elegans) 
and fly (Drosophila melanogaster) models, non-mammalian species as zebrafish (Danio 
rerio) and mammals, such as mouse (Mus musculus) and rat (Rattus norvegicus), have also 
been genetically engineered to express the HD mutation (80–83). A large number of mouse 
models of HD that show different degrees of similarity to the human condition have been 
generated. Models that express either truncated, full-length human or mouse mHtt display 
significant phenotypic differences that may be caused by the influence of the protein context, 
mouse strain, or regulatory sequences between the mouse and human HTT genes (80). To 
overcome these problems, a group of researchers also considered the generation of large HD 
genetic models such as sheep (84), mini-pig (85), and the non-human primate (86, 87). With 
their size, organ capacity, and physiology resembling in several aspects that of humans, these 
models may be well suited for preclinical trials and long-term safety studies. However, in 
some cases, ethical concerns have been raised. In this section, we describe especially the most 
common HD mouse models that have particularly enlightened in the search for targets and for 
compounds capable of interfering with mHtt toxicity. 
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1.5.1. Transgenic models  
 
In transgenic mouse models, full-length or a fragment of the mutant HTT gene is 
inserted randomly into the mouse genome, leading to the expression of a mutant protein in 
addition to the endogenous Htt. Thus, transgenic mouse models of HD express N- terminal 
mHtt fragments or full-length human HTT gene with an expanded polyQ tract (28).  
 
1.5.1.1. N-terminal huntingtin transgenic models  
 
The first transgenic mice model of HD, named R6/2 mice, include the insertion of a 
fragment of the human HTT gene. R6/2 mice contain a mutant N-terminal segment of the 
exon 1 of the human HTT gene with ∼144-150 CAG repeats (6). These mice display 
choreiform-like movements and mHtt inclusion formation as early as at 4-5 weeks. At 6-8 
weeks their physical appearance deteriorates and motor symptoms become very severe, 
followed by an early death around 12-14 weeks. Despite their severe motor impairment and 
brain atrophy, these mice display fewer neuronal death when compared to human HD patients 
(6, 79, 81). Due to their high number of CAG repeats, R6/2 mice seem to recapitulate the 
disease features of juvenile cases of HD (88). In parallel, another transgenic model was 
developed - the R6/1 model of HD. This mouse model expresses a truncated HTT gene with 
around 115 CAG repeats, and exhibits a progressive pathology and lower expression of the 
mutant transgene. A marked decline in rotarod performance and other locomotor activities is 
observed at 13-20 weeks, correlating with the numbers of striatal neurons exhibiting 
intranuclear inclusions of mHtt, and with death occurring within 4-5 months of age (8, 28). 
The R6/1 model is not used as often as the R6/2 model and is therefore less well understood. 
The N171-82Q mouse model of HD contains a longer N-terminal fragment of mHtt 
(exon 1 and exon 2) with 82 CAG repeats. Its lifespan is ∼17-20 weeks with HD-like 
symptoms beginning at 10-12 weeks of age. In these mice, neuropathological features are 
more similar to human HD, therefore brain atrophy and neuronal loss is more prominent and 
seems more selective for the striatum (78, 81). HTT is driven from a prion promoter, 
restricting expression solely to neurons and not glia. But in human HD, Htt is expressed in 
both neurons and glia (80). 
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1.5.1.2 Full-lenght huntingtin transgenic models  
 
Transgenic mice expressing full-length htt have in some cases been more successful 
than N-terminal fragment models regarding neuronal deterioration and loss and the capability 
to recapitulate more closely the sequence of events leading to HD. Two genomic transgenic 
models expressing full-length mHtt from the human genomic locus on a yeast artificial 
chromosome (YAC) (64, 89, 90) or on a bacterial artificial chromosome (BAC) (91) were 
generated. A series of YAC transgenic models of HD expressing full-length human mHtt with 
18, 46, 72, and 128 CAG repeats (i.e., YAC18, YAC46, YAC72, and YAC128) were created 
after microinjection of YAC DNA construct into the friend virus B strain (FVB/N) pronuclei 
and maintained on the inbred mouse FVB/N background strain; in contrast to the C57BL/6 
background strain common to most HD mouse models, the FVB/N strain shows higher 
neuronal loss when exposed to excitotoxic stress after injection of kainic- or quinolinic acid 
(QA) (64, 89, 90). YAC128 mice are the latest of the series and exhibit by far the most robust 
phenotypes among all the YAC models; therefore, YAC128 is used as a preclinical model in 
HD (89). At the protein level, the YAC128 line expresses human mHtt at about 75% of the 
level of the endogenous murine Hdh (80). YAC128 mice exhibit hyperactivity at 2 months of 
age and hypoactivity at 8–12 months of age. They also exhibit rotarod deficits at 4 months of 
age, which become more prominent at 6 months of age (92–94). mHtt nuclear localization is 
detected in the striatum at 1-2 months and in the cortex and hippocampus at 3 months of age. 
Nuclear inclusions are detected only at 18 months in the striatum. As in humans, selective 
atrophy in the striatum and cortex, but not in cerebellum is detected (93).  
BACHD, the model we have used in this study, is a more recent generated transgenic 
mouse model of HD and also maintained in the FVB/N background strain.  Under the control 
of endogenous HTT regulatory machinery on the BAC, the 97 polyQ repeat within full length 
mHtt in BACHD mice is encoded by a mixed CAA-CAG repeat, which is stable in both the 
germline and somatic tissues including the cortex and striatum at the onset of neuropathology 
(91). The BACHD mice exhibit progressive motor deficits and selective late-onset 
neuropathology without somatic repeat instability in the aged brain. BACHD mice exhibit 
mild rotarod deficits at 2 months, with progressive deficits and hypoactivity at 6 months of 
age. At 12 months of age, cortical and striatal atrophy is detected. However, unlike previous 
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full-length mHtt mouse models, BACHD mice do not show early and diffuse mHtt inclusions 
(91, 95). By 12 months of age, BACHD brains have only a few small aggregates 
predominantly in the neuropil in the cortex and small aggregates in the striatum (82), 
suggesting that diffuse nuclear accumulation of aggregated mHtt in striatum and cortex is not 
necessarily associated with the slowly progressive and selective pathological process in the 
BACHD mice. Importantly, a relatively steady-state level of predominantly full-length mHtt 
and a small amount of mHtt N-terminal fragments, present in both the nucleus and cytoplasm, 
may be responsible for the onset of neuropathology (91, 96). Thus, BACHD mice represent a 
robust in vivo paradigm to study HD pathogenesis and treatment. 
 
1.5.2. Knock-in models  
 
Knock-in HD models were generated by targeting an expanded polyQ repeat and/or 
adjacent human mHtt exon 1 sequences (including the polyP region) to replace the 
corresponding sequences in the endogenous murine HD homologue gene (Hdh) (97). 
Therefore, differently from the transgenic model, the mHtt in the Knock-in models is 
expressed from the endogenous Hdh locus in a similar manner to the expression in HD 
patients, making this model considered one of the most precise genetic HD mouse models 
(98).  When compared to N- terminal mHtt fragments expressing models, Hdh knock-in mice 
display slow progression and moderately mild phenotypes, and their lifespan is usually 
normal. This mouse model is important to evaluate early pathological processes induced by 
mHtt in humans (95). The first knock-in models generated were disappointing to the 
community because their extended stretch of 50 or 80 CAG repeats into the endogenous 
mouse Hdh gene (HdhQ50; HdhQ80) showed no behavioural phenotypes or abnormalities, or 
even mHtt aggregates (99, 100). For these reasons, other knock-in models were generated to   
better represent the human pathology. 
 
1.5.2.1. HdhQ111  
 
The HdhQ111 model is a knock-in mouse model of HD with an insertion of a chimeric 
murine Hdh/human mHtt exon 1 into the endogenous Hdh locus; the human mHtt portion 
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includes 111 CAG repeats and a polyP region (88). The behavioral phenotypes of HdhQ111 
are very mild and slowly progressive. Rotarod, clasping or open field abnormalities were not 
detected in heterozygous or homozygous HdhQ111 mice until 17 months of age, and gait 
abnormalities were detected only at 24 months of age (101). HdhQ111 homozygous mice 
show selective and progressive accumulation of nuclear mHtt at 2.5 months of age, nuclear 
inclusion formation at 10 months of age, and reactive gliosis in the striatum at 24 months of 
age (101). 
 
1.5.2.2. CAG140 
 
The CAG140 HD knock-in mice model was generated by replacing the endogenous 
murine Hdh exon 1 with a chimeric mouse and human exon 1 with 140 CAG repeats (102). 
CAG140 HD mice display early hyperactivity at 1 month of age, followed by hypoactivity at 
4 months of age, gait abnormality at 12 months of age, with nuclear mHtt micro-aggregates in 
the striatum and cortex, and nuclear inclusions in the striatum at 4 months of age and in the 
cortex at 6 months (103). However, nuclear micro-aggregates were also observed at 6 months 
of age in the cerebellum, a relatively spared region in human HD brain, but presented no cell 
loss or brain atrophy (95, 103). 
 
1.5.2.3. Hdh(CAG)150  
 
Hdh(CAG)150 HD knock-in mice was developed by a replacement of the short CAG 
repeat in the murine Hdh exon 1 with a stretch of 150 CAG repeats (104). Homozygous 
Hdh(CAG) 150 mice revealed several slowly progressive motor abnormalities (105, 106). 
Homozygous HdhCAG(150) mice display progressive rotarod deficits at 18 months of age 
and mHtt aggregates in the striatum and hippocampus at 6 months and widespread in the brain 
at 10 months of age (107).  Striatal neuronal loss is observed at 100 week-old (105).  
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1.6. Diagnosis, Screening and Prevention of HD  
 
HD is easily diagnosed based on the appearance of physical symptoms specific to the 
disease. As previously described, the motor symptoms are the first clinical features to be 
diagnosed, specifically abrupt, excessive and random timing of involuntary movement (26). 
Characterized by its dominant inheritance, the available genetic test for HD consists of a 
simple blood examination to confirm the number of CAG repeats in the HTT gene. However, 
a positive result is not considered a differential diagnosis since it can be obtained before the 
onset of symptoms. This test is very important to rule out the disease and also because its 
result may dramatically influence personal and family planning decisions. Longitudinal 
analyses show a consistent increase in the prevalence of HD over the past two decades, 
coinciding with wider availability of the genetic test. Since HD is an autosomal dominantly 
transmitted disorder, there is a 50 % chance of children from an affected individual inheriting 
the disease (15, 26). Prenatal testing can also be performed using non-invasive techniques to 
determine the carrier status of the fetus. The progression of the disease can be measured based 
on the unified HD rating scale (UHDRS) that characterizes the relevant clinical features of 
HD (108). Medical functional imaging, such as fMRI and PET, are very important in the early 
detection of HD since they can show changes in the brain activity before symptoms onset in 
addition to monitoring the disease progression (15, 26).  
HD is devastating to patients and their families and unfortunately, at the present, there 
is no effective treatment to stop or slow the disease progression.  
The current available therapies act mainly on motor symptoms in order to improve 
patients’ quality of life. These therapies are mainly focused to treat movement disorders such 
as chorea and dystonia, as well as gait, speech, swallowing and fine motor tasks (16). The 
only drug currently approved and specifically licensed by the US Food and Drug 
Administration (FDA) in 2008 to treat chorea in HD patients is tetrabenazine (109). As a 
synaptic vesicular amine transporter inhibitor, tetrabenazine acts by reducing the quantity of 
dopamine released from vesicles in the brain by reversibly inhibiting the monoamine 
transporter type 2 (VMAT2) and therefore depleting central monoamines (110). 
Tetrabenazine is also responsible for reducing dopamine by blocking dopamine receptors. 
Unfortunately, this drug is also associated with some adverse side effects, namely, sedation 
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and somnolence, agitation, depression, akathisia, anxiety and hyperkinesia (108, 110). Several 
studies are underway to investigate other potential treatments for chorea in patients with HD, 
including pallidal deep-brain stimulation (111, 112) and a deuterated tetrabenazine molecule 
(111, 113, 114). In fact, many reviews have emphasized the weak evidence supporting any 
other pharmacological intervention in the treatment of HD (115, 116). 
In an effort to diminish therapeutic nihilism in the absence of established and 
accurately proven treatments, a series of algorithms for the treatment of chorea, irritability and 
obsessive–compulsive behaviors were reported in 2011 by an international group based on 
surveys of HD experts (117). Until better treatments arise, the clinicians must adopt an 
attitude that therapeutics providing benefit to patients without HD, who have neuropsychiatric 
symptoms, may be also expected to help HD patients that share the same symptoms. As an 
example, some pharmacological approaches to treat or ameliorate the neuropsychiatric 
symptoms in HD include: olanzapine for weight loss, selective serotonin reuptake inhibitors 
and mirtazapine for depression, antipsychotic drugs for psychiatric and behavioral aspects of 
this pathology. Although these pharmacological compounds are not specific for HD (116), 
clinicians should proceed thoughtfully to optimize the patients’ quality of life with available 
medications and supportive therapies.  
 
1.7. Novel Strategies for Therapeutic Intervention in HD  
 
In this section I briefly describe new possible and promising therapeutic targets as well 
as potential disease-modifying therapies underlying the pathobiology of mHtt, that are 
currently being studied. Figure 4 highlights some of the current and potential disease-
modifying strategies for HD. Special emphasis will be given to chaperone-mediated folding 
and aggregation, and also pathways involving protein homeostasis, since it is the central topic 
for this thesis work. 
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Figure 4. Current priority preclinical therapeutic targets under investigation for Huntington 
disease. Several targets have been identified for potential exploitation in therapy, with strategies that 
include Htt lowering and immunomodulation (118) . Ac, acetyl group; ASO, antisense 
oligonucleotide; BDNF, brain-derived neurotrophic factor; CB2, cannabinoid receptor 2; EAAT2, 
excitatory amino acid transporter 2; GM1, monosialotetrahexosylganglioside; HDAC4, histone 
deacetylase 4; JNK, c-Jun N-terminal kinase (MAPK8, MAPK9 and MAPK10); KMO, kynurenine 3-
monooxygenase; MAPK, mitogen-activated protein kinase; NMDA, N-methyl-d-aspartate; P, 
phosphate group; p38, mitogen-activated protein kinase (MAPK11, MAPK12, MAPK13 and 
MAPK14); PDE, phosphodiesterase; PPAR-γ, peroxisome proliferator- activated receptor-γ; RNAi, 
RNA interference; Su, sumoyl group; TrkB, tyrosine receptor kinase B. Figure adapted from (26).  
 
1.7.1. Protein Homeostasis 
 
Protein homeostasis is essential for cell function and survival, because proteins are 
involved in all aspects of cellular function varying from cell metabolism and cell division to 
the cellular response to environmental stressors. Protein homeostasis is tightly regulated by 
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the synthesis, folding, trafficking and clearance of proteins, all of which act in an orchestrated 
manner to ensure proteome stability (119). The protein quality control system is composed of 
stress response pathways, which take action whenever the proteome is challenged by 
environmental or physiological stress. Aging, however, damages the proteome, and such 
damage is thought to be associated with age-related diseases. In the next sections I will 
discuss the different cellular processes that define the protein quality control system and focus 
on their role in protein conformational diseases. 
 
1.7.2. Protein Quality Control Systems  
 
Dysregulation of protein quality control is a key event in HD pathogenesis. The 
accumulation of misfolded proteins is a hallmark of many human diseases, including several 
incurable neurological disorders, such as HD. In HD, expansion of the polyQ stretch within 
the first exon of the Htt protein leads to Htt misfolding, aberrant protein aggregation, and 
disease onset (50). The accumulation of aberrant mHtt and other polyQ disease proteins form 
insoluble aggregates and, as mentioned above, the role that aggregation has in the 
pathogenesis of polyQ diseases remains contentious (50, 73, 122). Neurons, as post-mitotic 
cells with a high metabolic activity, are extremely sensitive to protein accumulation and the 
presence of aberrant proteins lead to neuronal cell death. Thus, the post-mortem confirmation 
of the presence of protein aggregates in the brain of patients with neurodegenerative diseases 
such as HD emphasizes the importance of protein turnover in neuronal homeostasis. To 
prevent the deleterious process of misfolded proteins accumulation, cells have specific quality 
control mechanisms that include the molecular chaperones, including the heat shock proteins 
(Hsps), the ubiquitin-proteasome system (UPS) activation, autophagy-mediated protein 
degradation. While chaperones help other proteins in the folding process, refolding misfolded 
proteins to their native conformation, the UPS and autophagy are responsible for the targeting 
and degradation of unfolded or mutant proteins (123). This degradation mechanism is critical 
to clear the cytosolic space from these toxic proteins that might disturb the essential cellular 
processes, and also to recycle amino acids (119, 123). Impairment of the cell quality control 
mechanisms is commonly associated with neurodegenerative diseases such as HD, and 
therefore the focus of intensive research in the field (119). 
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1.7.2.1 Heat Shock Proteins (Hsps) 
 
Hsps, are able to bind specifically and non-covalently to interactive proteins surfaces 
that are transiently exposed during cellular processes (124). The controlled binding and 
release of substrate proteins facilitates the correct fate of the protein in the cell, whether this 
be correct folding assembly into oligomers, transport to a specific subcellular compartment, 
membrane translocation, or even degradation (125). Hsps protect the cells against a variety of 
stresses by preventing abnormal protein aggregation and by keeping proteins in a state 
competent for either refolding or degradation (121). Some chaperones interact with a variety 
of polypetide chains, whereas other act on specific targets via substrate specific binding 
domains. For example the 70 kDa Hsps recognize hydrophobic protein surfaces or amino acid 
residues that are generally exposed by non-native proteins and newly synthesized polypeptide 
chains (126). The ClpX/Hsp100 family can illustrate an example of specificity of some 
molecular chaperones. Proteins of this family form ring-like subunit architectures and are able 
to disassemble multimeric or aggregated forms of certain proteins in an ATP dependent 
fashion (127). Two members of this family (Clp X and ClpaA) recognize specific C-terminal 
sequences on target proteins. This property has been extensively characterized for the 
interaction between E.coli Clp X and the transposase of phage Mu (MuA protein) (128). 
Molecular chaperones were originally termed Hsps due to their initial discovery in 
Drosophila melanogaster cells exposed to elevated temperatures. Despite the name, the Hsps 
are also known to be induced by a wide variety of environmental or metabolic stresses 
including anoxia, ischemia and viral agents (121, 129). Hsps can be divided into ATP 
dependent and ATP independent families as well as being subdivided into families according 
to their molecular weight. The ATP-dependent Hsps require ATP hydrolysis to facilitate the 
folding process (129).  
 
1.7.2.1 Hsp families 
 
The name of the members of the Hsp family is derived from the molecular weight of 
the main representative protein (Table 1) (121, 130). Additionally, the nomenclature is based 
on systematic gene symbols that have been assigned by the HUGO Gene Nomenclature 
Committee (HGNC) (131). 
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Table 1. Major families of Hsps  
 
Different Hsps families recognize structural features that are specific to immature and unstable 
proteins at different of folding and unfolding. The Hsp70 chaperones, rin-shaped chaperonins and 
Hsp90 are involved successively more advanced stages of protein folding and function, whereas the 
small Hsps and Hsp100 act predominantly during stress (132). 
 
1.7.2.3. Small heat shock proteins (sHsps) family 
 
Small heat shock proteins (sHsps) have molecular weights between 12 and 43 kDa, 
distinguishing them in size from larger Hsps (133, 134). There are ten human sHsps: HSPB1–
HSPB10 (134, 135). They share common structural characteristics, including a highly 
conserved 90 amino acid long Hsp20 domain, usually referred to as the alpha-crystallin (α-
crystallin) domain, and the capacity to form large dynamic oligomers (136). Thus, sHsps can 
be found as homo- or heteromeric complexes, consisting of 2-40 subunits (137). The α-
crystallin domain consists of two layers of three and five anti-parallel strands, respectively, 
connected by a short inter-domain loop, forming a β-sheet (138). The α-crystallin domains of 
two monomers interact tightly to form dimeric building block of the sHsp oligomers. The N-
terminal region contains α-helical components and is variable in structure (139). The N-
terminal of many of the sHps contains a small prolinephenylalanine-rich region with one or 
two WD/EDF motifs. This region seems to be important in oligomeric complex formation and 
also for chaperone activity (140). The C-terminal tail is highly motile and flexible, and is also 
involved in stabilizing the oligomeric structure through contacts between a conserved motif in 
the C-terminal region and a hydrophobic patch in the α-crystallin domain of a neighboring 
subunit (139).  
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 As chaperone proteins, sHsps bind misfolded proteins and prevent them from 
aggregating. However, they are unable to actively refold the protein themselves because in 
contrast to other Hsps families, the sHsps do not require ATPase activity for their chaperone 
function (141). Instead, sHsps sequester the misfolded proteins within the cell, forming large 
dynamic oligomeric structures that are able to bind several non-native proteins per oligomeric 
complex, to prevent aggregation until a large Hsp, as Hsp70 or Hsp40, can assist in refolding 
(134, 137, 142) (Figure 5). 
 
Figure 5. Mechanism 
of sHsp chaperone 
interaction with 
amorphously 
aggregating target 
proteins sHsps 
selectively interact with 
and stabilize slowly 
aggregating, 
intermediately folded 
target proteins on their 
amorphous off-folding 
pathway. The 
intermediates (I2 ) are 
relatively disordered in 
structurewith only some 
elements of secondary 
structure in place.The 
dynamic nature of the 
equilibrium between the monomeric and aggregated I2 species facilitates interaction with the similarly 
dynamic sHsp. There is some evidence that the dissociated, dimeric form of the sHsp is the chaperone-
active species which interacts with I2 and is subsequently sequestered into a high-mass complex 
containing both proteins. It is possible to recover natively folded target protein (N) via the action of 
another chaperone, for example by Hsp70 action coupled to ATP hydrolysis (124, 137). 
 
 
Historically, sHsps have been extensively studied in the context of being intracellular 
molecular chaperones. However, recent studies looking at the role of sHsps in neurological 
diseases have demonstrated that despite being found in areas of damage, sHsps show 
therapeutic effects by transgenic overexpression and exogenous administration in various 
experimental disease paradigms (143). In addition to acting as molecular chaperones and 
preventing protein aggregation, sHsps have been suggested to be strongly involved in 
	  	  	   23	  
apoptosis inhibition, anti-inflammation, organization of the cytoskeleton (134, 137). The most 
intensively studied sHsps are the Hsp27 or HSPB1 and αB-crystallin (αBc) or HSPB5 (144). 
 
1.7.2.4. αB-crystallin/HSPB5 
 
αB-crystallin (αBc) or HSPB5 is a ubiquitously expressed protein and is a major 
constituent of the eye lens (145), and in the brain is mainly expressed in astrocytes and 
oligodendrocytes (146). 
αBc acts as a molecular chaperone by preventing the aggregation of unfolded proteins 
and is know to be a multi-tasking chaperone by playing a role in several cellular functions: 
protein turnover, redox homeostasis, apoptosis and inflammation inhibition, cytoskeletal 
assembly and architecture (147). It is associated with cytoskeleton proteins, for example, αBc 
modulates the assembly of the intermediate filament protein vimentin, of the glial fibrillary 
acidic protein (GFAP) and stabilizes actin filaments in a phosphorylation-dependent manner 
(148). In addition, αBc also associates with tubulin, and microtubule-associated protein 
(MAP) and this is mediated through the α-crystallin domain (149, 150). αBc might play a role 
on proteosome degradation, UPS pathway, since it has been found to interact with FBX4, and 
F-box-containing protein that is a component of the ubiquitin-protein isopeptide ligase SCF 
(SKP1/CUL1/F-box). This interaction is dependent on phosphorylation of αBc (151). The 
chaperone activity or cytoprotective activity of αBc can be regulated by phosphorylation. 
Interestingly, in the brain, some of the αBc isolated from the proteinaceous aggregates of 
patients with amyloid plaques and Lewy bodies is phosphorylated (152). However, it remains 
unclear whether there is a preference for the phosphorylated forms of αBc to interact with the 
proteins associated with these deposits (153). 
αBc has three phosphorylation sites, serines 59, 45, and 19 (153). The triple 
phosphomimic of αBc (i.e. S19D, S45D, S59D αBc or 3D αBc) is a more effective chaperone 
in preventing fibril formation by the natively unstructured target proteins k-casein and α-
synuclein compared to the WT protein, but is less effective against the ccb-Trp peptide which 
adopts a well-structured coiled-coil configuration in its native state prior to fibril formation 
(154). 
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At the least two pathways are implicated in αBc phosphorylation: the MAPKAPK2 
kinases phosphorylate serine 59 whereas serine 45 may be regulated by p42/p44 MAPK. The 
kinase involved is the phosphorylation of serine 19 is still unknown (140) (Figure 6). 
 
           
Figure 6. Domain structure and biochemical properties of αB-crystallin (αBc).  
A) Light box - conserved region in N-terminus; black box - α-cystallin domain; grey box – WDPF 
domain; ^^^ - flexible domain; P – phosphorylated serine residues. Arrows indicate positions of point 
mutations that are responsible for pathologies. B) Biochemical properties of sHsps. Large oligomeric 
structures are favored under conditions of stress and associate with unfolded proteins. Phosphorylation 
decreases the size of the oligomers. Large non-phosphorylated oligomers of αBc (and Hsp27) (>300 
KDa) can protect cells through their chaperone activity, and small oligomers may act at the level of F-
actin polymerization/depolymerization (133). 
 
Mutations in the sHsps, namely in αBc, have been reported in a number of human 
diseases. Some of these mutations have been found as genes responsible for human 
degenerative myopathy, cardiomyopathy and congenital cataracts (Table 2). Regarding the 
myopathies, recent studies have revealed the importance of αBc towards desmin network 
(148, 155). The majority of mutations found in αBc (and other sHsps) are contained in the 
conserved α-crystallin domain, suggesting that oligomerization and chaperone function of 
αBc is impaired (156).  
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Table 2. Mutations in αBc and the corresponding pathologies. Adapted from (144). 
Mutations Associated Pathologies Ref 
R120G Myofibrillar myopathy, cardiomyopathy, cataract (155) 
Q151X Myofibrillar myopathy (157) 
464delCT Myofibrillar myopathy (157) 
R157H Cardiomyopathy (158) 
PS20S Cataract (159) 
D140N Cataract (160) 
450delA Cataract (161) 
 
The crystal structures of αBc and other sHsps may provide insights into understanding 
how some of these mutations have pathological consequences (162). 
 
In the absence of αBc, knockout mice show normal lens development and age-related 
degeneration of skeletal muscle, but otherwise have no overt phenotype (163). A recent study 
however show αBc -/- mice to be more susceptible to experimental autoimmune 
encephalomyelitis (EAE) - mouse model of Multiple Sclerosis (MS), with an increase in 
inflammation and glial apoptosis (153). This study enlightens the anti-inflammatory 
properties of αBc and suggested its therapeutic effect in autoimmune diseases. In addition, 
αBc has anti-apoptotic functions through its potential interactions with the p53 and caspase-3 
pathway (164, 165). Its expression is also correlated with TRAIL resistance in a number of 
human cancer cell lines (166). Several studies have highlighted αBc antioxidant properties 
and its role in preventing oxidative stress, αBc was able to reduce the levels of hydrogen 
peroxide (H2O2) on a study in C6 astroglioma cell lines (167). In addition, an oligomer of αBc 
was reported to bind Cu2+ with close to picomolar affinity and to sequester a large number 
(~150) of Cu2+ ions. Therefore acting like a “Cu2+ sponge”, αBc has been shown to inhibit 
Cu2+- induced oxidation of ascorbate and hence preventing the production of oxygen species 
(168). Due to the diverse protective properties of αBc, intensive research has shown the role 
of endogenous αBc in various pathologies (147). However, recent studies have used 
recombinant αBc and its peptides as therapeutic agents for diseases including 
neurodegenerative diseases, myopathies, inflammation, stroke, retinal pathology, platelet 
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aggregation, and H2O2-injury by transgenic overexpression or exogenous administration using 
in vivo and in vitro models (132, 133, 147).  
Whether or not the endogenous release of αBc from cells occurs is still unclear. The 
primary sequence of αBc does not have a peptide signal sequence and therefore whether αBc 
can be secreted remains in debate. Nevertheless, several studies have reported the 
extracellular presence of several sHsp (169–171). Interestingly, extracellular lipoprotein 
drusen deposits and the inter-photoreceptor matrix contain αBc as a component, suggesting an 
extracellular function for αBc (172). Supporting this data, the apical secretion of αBc was 
reported in a non-conventional pathway via exosomes in polarized retinal pigment epithelial 
(RPE) cells (173), and it was also demonstrated that αBc efficiently neutralized extracellular 
misfolded oligomers and suppressed oligomer-induced toxicity (174). This insight has 
highlighted the possibility of αBc as novel therapeutic target for HD and other 
neurodegenerative diseases. 
 
1.7.2.5.  αB-cystallin in Neurodegenerative Diseases and other CNS injuries  
 
Mounting evidence over the past two decades suggests that αBc may not only play a 
role in maintaining a healthy body, but that they also have protective functions in disease or 
injury to the central nervous system (CNS) (132, 133, 175).  
Important findings and support to my thesis work resulted from a study conducted in a 
mouse model of Alexander disease (AxD), a primary disorder of astrocytes caused by 
dominant mutations in the GFAP gene. In this study, loss of αBc led to increased mortality, 
while overexpression of αBc rescued animals from terminal seizures (176). Remarkably, in 
this model, restoration of αBc expression through the GFAP promoter reversed this lethal 
outcome, showing the rescue effect is astrocyte-specific. Overexpression of αBc results in a 
markedly reduced CNS stress response, restores expression of the glutamate transporter Glt1 
(EAAT2), and protects these animals from death (176, 177). Several other studies reporting 
the therapeutic and protective role of αBc in devastating neurological disorders and other 
CNS injuries has been widely studied (Table 3). 
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Table 3. Therapeutic role of αBc in neurological disorders and other CNS injuries. 
Disease Model  Delivery/ Administration Route Therapeutic Efficiency Ref 
Huntington’s
Parkinson’s 
diseases 
WT and gmr Q92, 
UAS- α syn 
Transgenic (Tg) 
Drosophila model 
P element-mediated germ line 
transformation with pUAS-
αBc-HA 
Suppressed compound eye: 
degeneration induced by polyQ &  
α- synuclein-induced rough eye 
phenotype  
(178) 
Alexander’s 
disease 
GFAPTg and 
GFAP+/R236H 
mouse model of 
Multiple sclerosis  
αBc over expression under 
GFAP promoter 
Reduced CNS stress response, 
restored expression of the Glt1 
Protected mice from terminal 
seizures – death 
(179) 
Parkinson 
disease, CNS 
inflammation 
Drd2-null mice, 
Drd2hGFAP cKO, 
cultured astrocytes, 
and Parkinson 
disease mouse  
αBC over expression under 
GFAP promoter in Drd2-null 
mice, and αBc over expression 
in cultured astrocytes null for 
Drd2. 
Suppressed the proinflammatory 
mediators like IL-1β, IL-2, IL-6, 
IFN-γ, and IL-12β Suppressed 
(180) 
Alzheimer’s 
disease 
Tg2576 Mouse 
model of AD 
CRYAB-/-;HSPB2-/- 
(αBc/HspB2 null mice) in AD 
Severed impaired locomotion 
Exacerbation of protein 
aggregation 
 in CRYAB-/-;HSPB2-/-; Tg2576 
mice 
(181) 
Multiple 
sclerosis (MS)  
EAE Mouse model 
of MS Intraperitoneum 
Decreased clinical score when 
administered at peak of disease, 
Reduced apoptosis in CNS 
(182–
184) 
Brain Stroke WT and CRYAB−/− mouse Intraperitoneum 
Reduced both stroke volume and 
inflammatory cytokines 
associated with stroke 
(185) 
Ischemic 
injury 
Myocardial 
Adult and neonatal 
Rat Viral vector Protected against ischemic injury  
Spinal cord 
contusion 
injury 
Mouse Intravenous 
Improvement in locomotor skills, 
amelioration of secondary tissue 
damage. Modulation of 
inflammatory response 
(186) 
H2O2 induced 
injury 
(Oxidative 
stress) 
Human lens 
epithelial (HLE) cells 
Pretreatment of HLE cells 
with gC-CPP tagged αBC (gC-
αBC) and TAT fused αBC 
(TAT-αBC) separately. 
Protected the HLE cells from 
oxidative stress induced cell 
death. 
(187) 
Endothelial 
injury & 
platelet 
aggregation 
Human platelet rich 
plasma (PRP) and 
hamster 
Incubation of PRP with αBC 
Intracellular 
Reduced thrombin-induced 
calcium influx and 
phosphoinositide hydrolysis by 
phospholipase C in human 
platelets 
(188) 
Optic nerve 
crush 
Endothelial 
Rat  Intravenous 
Increased the number of retinal 
ganglion cells (RGCs), decreased 
the number of retinal microglial 
cells (RMCs), and decreased the 
protein expression of TNF-α, 
iNOS. Reduced 
(189) 
CNS: central nervous system; Drd2: dopamine D2 receptor; EAE: experimental autoimmune 
encephalomyelitis; GFAP: glial fibrillary acidic protein; RGC: retinal ganglion cells.  
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Because of the beneficial effects of αBc in many neurodegenerative diseases and other 
pathologies as well, αBc is a molecule of great interest in the field. In the context of HD, the 
main focus for this study, αBc has show neuroprotective effects on different polyQ proteins: it 
has prevented the in vitro aggregation of ataxin-3 (190), and it has supressed the mHtt-
induced toxicity in mice lens (191). In more detail, expression of the mHtt fragments 46Q and 
72Q in mice lacking this major lens chaperone, αBc, markedly accelerated the onset and 
severity of aggregation, leading to cataracts. This demonstrated that the endogenous 
chaperone activity of  αBc suppresses aggregation in vivo (191). 
 In addition, studies conducted in a transgenic Drosophila model have shown that αBc 
overexpression suppressed both polyQ-induced compound-eye degeneration and α-synuclein-
induced rough-eye phenotype, suggesting a protective role for αBc in HD and Parkinson’s 
diseases (178).  
Although many studies have examined the expression and modulation of αBc in 
neurological diseases, to date the potential neuroprotective role of αBc has not been tested in 
vivo in a mouse model of HD. Hence, this thesis will focus on deciphering the role of αBc in 
the progression of the disease of the BACHD mouse model of HD. 
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Aims of the project  
 
As introduced earlier, HD is a devastating neurodegenerative disorder. How the 
polyQ-expanded mHtt causes selective and progressive dysfunction and neurodegeneration 
remains unclear. Therefore, at the present there is no cure for HD. 
Protein misfolding and aggregation of mHtt play a central role in HD, and growing 
evidence has been shown that transgenic overexpression and exogenous administration of the 
sHsp αBc may represent a strong candidate for HD therapeutic targets.  
The main aims of this project were to investigate whether modulating the levels of 
αBc affected mHtt toxicity and influenced pathogenesis in a mouse model of HD. Thus, the 
aims of this thesis were: 
 
1. Determine whether αBc overexpression in astrocytes affects the onset and 
severity of HD phenotype and neurotoxicity induced by mHtt in vivo (Chapter 3) 
 
We tested whether astrocytic αBc overexpression was able to modulate behavioral 
and neuropathological deficits in a mouse model of HD. Thus, we crossed the well 
characterized BACHD mouse model of HD with αBc transgenic mice in which αBc is 
regulated by the GFAP promotor, driving its expression in astrocytes. 
 
2. Explore the relation of αBc overexpression with fundamental cellular pathways 
that are impaired in HD  
(Chapter 4) 
 
We clarified important cellular mechanisms where αBc could potentially be involved 
in alleviating mHtt-induced toxicity. We investigated potential αBc interactors in the 
progression of HD. 
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3. Determine whether αBc deficiency affects the onset and severity of HD phenotype 
and neurotoxicity induced by mHtt in vivo  
(Chapter 5) 
 
We tested whether endogenous αBc was able to modulate behavioral and 
neuropathological deficits found in the BACHD mouse model of HD. Thus, we crossed 
BACHD mice with αBc deficient mice (αBc-/-). This KO model also targets HspB2, due to 
the proximity of the promoter sequences of both sHsps genes.  
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3.1. Introduction 
 
Huntington’s disease (HD) is a fatal autosomal, dominantly inherited, progressive 
neurodegenerative disorder (1). The mutation responsible for HD leads to abnormally long 
CAG/polyglutamine (polyQ) repeats in the IT15 gene, which encodes the ubiquitously 
expressed protein huntingtin (Htt) (2). The polyQ expansion makes Htt prone to misfold and 
accumulate, which is thought to confer a toxic gain of function (3). The deposition of 
inclusion bodies of misfolded Htt fragments containing the expanded polyQ region is a 
neuropathological hallmark of HD (4).  
This accumulation of misfolded proteins in cells triggers a protective stress response 
that includes the up-regulation of heat shock proteins (Hsps) that function as molecular 
chaperones either to prevent protein misfolding or to rescue misfolded proteins to help restore 
cellular homeostasis (5, 6). Overexpression of molecular chaperones reduces Htt aggregation 
and increases lifespan in HD Drosophila and mice (7–10). Manipulating the expression of 
chaperones that mitigate protein misfolding or facilitate its clearance may represent an 
approachable therapeutic target to decrease toxicity and slow disease progression in HD 
models.  
The small Hsp (sHsp) family of molecular chaperones includes proteins of small 
molecular mass (15–30 kDa) that accumulate in the cells after many different environmental, 
physiological or pathological stresses (11). sHsps are protective in many pathways that are 
implicated in HD, including native and non-native protein folding, cytoprotection from 
numerous stresses, such as oxidative damage and modulation of cell death and survival 
pathways (6). Structurally, all sHsps share a central C-terminal domain, referred to as the 
alpha-crystallin domain, consisting of 80–90 residues in eight beta strands that form an 
intermolecular beta- sheet interaction site (12, 13). The most studied sHsps (i.e., 
Hsp27/HSPB1, αA-crystallin/HSPB4, αB-crystallin/HSPB5, Hsp22/HSPB8 and 
Hsp16.2/HSPB11) have strong anti-aggregation chaperone activity through their ability to 
recognize and interact with partially folded protein intermediates (14, 15). Chaperones include 
eligible candidates for neuroprotection in HD (6, 16), and their potential has been evaluated in 
vitro (17), in Caenorhabditis elegans (18), mammalian cells (8, 19), and in vivo models of HD 
(20). Our study focused on the αB-crystallin (αBc) or HspB5 protein. This sHsp has a 
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chaperone-like function and binds to the unfolded proteins to inhibit its aggregation (21), 
suggesting that αBc has an impact on several protein conformation disorders. αBc prevents 
the aggregation and elongation of α-synuclein fibrils (22, 23), implicated in Parkinson’s 
disease (PD). Furthermore, αBc is a potent inhibitor of amyloid fibril formation and, by 
slowing the rate of its aggregation, effectively reduces the toxicity of amyloid-β peptide in 
cells (24), suggesting a protective role for αBc in a Alzheimer’s disease (AD) in vitro model. 
Amyotrophic lateral sclerosis (ALS) is a progressively paralytic neurodegenerative disease 
that can be caused by mutations in Cu,Zn-superoxide dismutase 1 (SOD1). Completely 
eliminating αBc in mice expressing two different SOD1 mutants (G37R and L126Z) reduced 
the interval to disease end stage by 20–30 days in mice expressing either mutant (25). These 
results suggest that the activity of αBc modulates the cellular specificity of mutant SOD1 
accumulation. In addition, over-expression of αBc in a mouse model of Alexander disease 
(AxD), a rare and fatal neurodegenerative disorder of childhood, rescued the AxD mice from 
terminal seizures. Consistently, loss of αBc resulted in increased mortality of these mice (26).  
 We previously showed that expressing a mutant Htt (mHtt) fragment in the lens of 
mice lacking αBc markedly accelerated the onset and severity of mHtt aggregation (27). In 
addition, overexpression of αBc in a transgenic drosophila model of HD suppressed mHtt 
toxicity, suggesting a protective role for αBc in HD (28). Downregulation of a number of 
molecular chaperones, including αBc, was reported in the brains of the exon-1 fragment 
mouse model R6/2 (20, 29), suggesting αBc may be associated with HD pathogenesis in vivo, 
and that restoration of chaperone levels could be neuroprotective against disease. 
Interestingly, current evidence suggests expression of the sHsps, such as αBc, is 
predominantly in non-neuronal cells (7). In the brain, αBc is mainly found in astrocytes and 
oligodendrocytes. The role of astrocytes and oligodendrocytes in HD is not entirely clear. 
However, evidence suggests that non cell-autonomous functions of glial cells are an important 
mechanism of supporting neuronal health (30). We focused on astrocytes because recent 
studies in different HD mice models have shown that astrocytes contribute to neuronal 
dysfunction in vivo, by a marked decreased expression of both glutamate transporters, 
GLAST and GLT-1, and of glutamate uptake (31), by a decrease on potassium (K+) ion 
channel expression in astrocytes and disturbances of astrocyte-mediated K(+) homeostasis 
(32) or by being a source of oxidative stress to neurons in vivo (33). 
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Here we investigated the effects of αBc overexpression in astrocytes on behavioral and 
neuropathological phenotypes in a full-length HD mouse model, BACHD. These mice exhibit 
early (2–3 months of age) robust and progressive motor deficits, and late-onset selective 
neuropathology, including significant cortical and striatal atrophy (34). αBc astrocytic 
overexpression in BACHD mice improved motor and cognitive symptoms. The improvements 
in behavioral deficits correlated with prevention of the cortical and striatal neuron loss that is 
observed in HD. We observed a decreased level of soluble mHtt, and decreased size of mHtt 
inclusions in BACHD brain. Our results suggest that αBc is protective in HD through an 
astrocyte-mediated chaperone function related to regulating mHtt protein levels and 
aggregation in BACHD brains.  
 
3.2. Materials and Methods  
 
Animals and breeding strategy 
 
Experiments involving mice were approved by the Institutional Animal Care and Use 
Committee of the University of California, San Francisco. Mice were housed, bred and 
maintained in compliance with National Institutes of Health guidelines. BACHD (BACHD tg) 
mice (34) were obtained from William Yang (University of California, Los Angeles). Cryab 
Tg (Cryab tg) mice with wild-type hamster Cryab gene under the control of the human GFAP 
promoter (35) were obtained from Albee Messing (University of Wisconsin, Madison). Both 
lines were maintained by breeding to WT FVB/NJ animals from the Jackson Laboratory (Bar 
Harbor, ME). To test if over-expression of αB-crystallin improved HD progression, we 
crossed the Cryab Tg mice to BACHD mice. Progeny from this breeding included Cryab Tg, 
BACHD, Cryab tg;BACHD (double transgenic, DTg) and littermate controls, wild-type (WT) 
mice and were used for behavioral studies and HD-associated neuropathological studies.  
 
Genotyping 
 
Mouse-tail DNA was analyzed by PCR to determine the genotypes. The BACHD 
transgene was identified as described (34). The Cryab transgene was identified as described 
(35).  
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Behavioral assays 
 
For all behavior experiments, experimenters were blinded to genotype. Experimental 
readouts were analyzed at 3, 7, 10 and 13 months for elevated plus maze, open field, rotarod 
and balance beam to evaluate HD phenotype progression. All cages contained at least one 
mouse from each genotype, and mice were given environmental enrichment. Mice were 
subject to a 12-h light/dark cycle. Behavioral analysis of WT, Cryab Tg, BACHD and DTg 
mice was done blind to genotype.  
Before starting the behavioral analyses at the first time point (3 months), two mice 
from our cohort presented tumors in their legs (one was WT and the other BACHD). In our 
water-T-maze study (at 13 months), one mouse (from the double transgenic - DTg group) was 
removed from testing because he was an aggressive male that bit the tester during the pre-
training phase. This mouse’s aggressive behavior resulted in the need to house this mouse 
singly and to be excluded from the last behavioral assay. In both cases, these mice were 
excluded but the exclusion was not based on behavioral performance and so did not introduce 
an obvious bias into the measurements. 
 
Elevated Plus Maze 
 The elevated plus maze has been described as a simple method for assessing anxiety 
responses in mice (36). Anxiety levels were measured in a cross-shaped maze, with two open 
arms and two closed arms linked to automated computer software. Entries and time spent on 
both open and closed arms were detected by photobeam arrays underlying the four arms 
platform. Each mouse had 3 sessions (15 min each) and returned to its initial cage after 
testing. Testing arms were cleaned with 70% alcohol after each session to remove any dirt or 
smell accumulated on the apparatus. 
To note: In our study, the BACHD mice did not display an anxious phenotype in the elevated 
plus maze test during the disease progression. 
 
Open field 
Spontaneous locomotor activity was measured using an automated Photobeam 
Activity System (San Diego Instruments, San Diego, CA). Before testing, mice were 
	  	   49	  
acclimated in the testing room for 1 h. During testing, mice were placed into a clear plastic 
testing chamber (41 × 41 × 30 cm) for 15 min. Horizontal and vertical movements were 
detected by photobeam arrays traversing the testing chamber. Testing chambers were cleaned 
with 70% alcohol after each session. 
To note: In our study, the BACHD mice did not display a locomotor phenotype in the open 
field test during the disease progression. 
 
Rotarod 
An accelerating rotarod (Med Associates ENV-577M) was used to analyze motor 
coordination and balance. Baseline behavior was performed at 3 months, and mice were 
placed into balanced cohorts based on sex, and genotype. Mice were trained three times at a 
constant speed of 16 rpm for maximum of 300 s. During testing, mice were subjected to beam 
acceleration of 4–40 rpm for a maximum of 300 s, three times per session (1 day) for a total 
of three sessions/days (37). Performance was quantified by measuring the latency to fall off of 
the rotarod apparatus. 
 
Balance beam 
The balance beam was also used to assess motor coordination and balance. This test 
consisted of three sessions with three trials in each session: one session of training, one 
session of testing on large diameter beam, one session of testing on medium diameter beam. 
Motor performance was assessed by measuring the time it takes for the mouse to traverse the 
beam, the number of hind paw slips, and the number of falls during this process (38). 
 
Water T-maze 
Normal phase swimming T-maze test  
The full-length mHtt model—YAC128 mice—show multiple cognitive deficits in 
swimming T-maze test (39). We decided to test cognitive deficits in BACHD mice at 13 
months. 
Mice were tested to assess spatial learning and memory. They were placed in the base 
of a water-filled T-maze and trained to swim to an escape platform located in the right or left 
arm of the maze (mice were divided in two groups and trained to reach the platform to the 
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right or to the left side to be unbiased in the test). Mice must learn to turn to the correct arm to 
reach the platform directly.  
During this test, mice received three trials per day for 7 days. To successfully 
complete this task, mice must remember either the location of or the path to the escape 
platform. Because FVB/N mice have severe retinal degeneration at the age tested (40), 
learning to swim to the correct arm of the maze likely relies on internal rather than external 
cues.  
Reversal phase swimming T-maze test  
After 1 day of rest, we included a reversal phase to the swimming T-maze test to 
assess the ability of the mice to replace a previously learned strategy. For this test, the 
platform was switched to the opposite arm (used in the first phase) of the T-maze. Mice 
received three trials per day for 5 days.  
For the two phases of the T-maze test, the time to reach the platform, the swim 
velocity and the distance taken to reach the platform were recorded. Swimming through the 
incorrect arm was arbitrarily given a score of 0, whereas swimming into the correct arm 
where the platform was located was given a score of 1. 
 
Protein extraction 
Mice were anesthetized with Avertin (tribromoethanol, 250 mg per kg) and perfused 
transcardially with 0.9% saline. Brains were removed, microdissected in ice-cold PBS, and 
homogenized in ice-cold standard RIPA buffer (150 mM NaCl, 1% NP-40, 0.1% sodium 
dodecyl sulfate, 0.5% sodium deoxycholate, 50 mM Tris, pH 7.4) supplemented with 
complete protease inhibitors (Roche Applied Science) and spun at 14,000 × g for 20 min at 4 
°C. 
 
Western blotting 
Proteins (10–20 µg/well) were separated on a 4–12% NuPAGE Bis-Tris gel (Life 
Technologies) and transferred onto nitrocellulose membranes, which were incubated for 1 h in 
5% bovine serum albumin (Sigma-Aldrich) diluted in Tris-buffered saline containing 0.05% 
Tween (BSA-TBST). Immunoblots were probed and incubated overnight at 4 °C in rabbit 
anti-αB-crystallin (1:1,000, Stressgen), or anti-B-tubulin (Abcam, ab6046, 1:20000), 4H7H7 
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(1:2000, made in the Lab), 1C2 (1:1000, made in the Lab) antibodies diluted in BSA-TBST. 
Appropriate IRDye secondary antibodies (LI-COR Biosci) were used at a 1:20,000 dilution. 
Images were captured with the Odyssey CLx (LI-COR Biosci). 
 
Neuropathology 
Mice were anesthetized with avertin (tribromoethanol, 250 mg/kg) and perfused with 
saline. Hemi-brains were then drop fixed in 4% paraformaldehyde for 48 h. For mHtt 
inclusions, multiple perfusion-fixed brains were embedded in gelatin blocks, post-fixed, and 
freeze-cut into coronal 35 µm sections in 24 sequential series (NeuroScience Associates Inc., 
Knoxville, TN). These were stored at -20° C in cryoprotectant as individual series of sections 
and stained for mhtt-derived aggregates with an affinity purified preparation of the sheep anti-
htt antibody S830 (30 ng/mL), GFAP (10 ng/mL) and Iba1 (10 ng/mL) under uniform free-
floating conditions modified from previous descriptions (41). Binding was visualized using 
ultra-sensitive HRP-based Ni++/DAB immunohistochemistry. Images (590 µ x 470 µ) were 
collected with a Nikon DS-RI1 Digital Sight camera on a Nikon Eclipse Ni microscope under 
control of NIS-Elements V4.30. Extended depth-of-field images were converted to gray scale 
and numbers and size of immunoreactive inclusion bodies determined using Fiji-ImageJ.  
 
For striatal and cortical counts: 
Fixed brains were sectioned into 40 µm sections with a Leica Vibratome in 24 sequential 
series. Free-floating sections were incubated in either 10% goat or donkey serum in 0.1% 
Triton X-100 for 1 h before incubation with primary antibodies at 4°C for 24 h. Sections were 
then immunostained with anti-DARPP32 (1:1000, Cell Signaling) and NeuN (1:1000, 
Chemicon). The specific areas analyzed were striatum/medial caudate/putamen and M1/M2 
cortex. For all neuropathological analysis, at least three sections were analyzed per mouse and 
for each section and each area (cortex or striatum), we obtained 6 to 7 fields of 
view/micrographs and cell counts were averaged per area/per mice. For comparison across 
genotypes, we selected sections from the same sequential series. Confocal micrographs for 
DARPP-32- and NeuN-positive cells were analyzed with original proprietary programs that 
were written in MATLAB.  
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The following steps used on a Matlab Script were used for all images from the different 
groups of mice, and analyzed simultaneously. 
(1) The script first reads the input image and filters it using an adaptive thresholding 
method based on the paper  "Adaptive Thresholding for the DigitalDesk" by Pierre Wellner 
(42). We used median filtering and relative thresholds instead of absolute as they gave more 
accurate results.  
(2) After thresholding, we end up with a binary image where the objects of interest are labeled 
with 1's. This image also has some noise in the form of small white objects that need to be 
removed. Hence, we use morphology to remove all objects that are smaller than 200 pixels in 
area. This helps clean up the thresholded image and we are left with the cells of interest (that 
will be examined/reviewed to counteract possible shrunken and smaller cells to avoid 
therefore a different cell count in one of the genotypes compared with the other; this revision 
is done blindly for each genotype). The images below illustrate the application of this 
algorithm to image data, and demonstrate that the program is capable of accurately identifying 
and counting cells as objects, despite a fairly wide variation in cell size and morphology. 
(3) After morphological cleanup, we still need to process these images further because there 
may be touching cells that need to be separated. This is done using a recursive watershed 
method to split merged objects, as described in (43) for the iterative watershed method. 
(4) At this point we now have separate objects in each image that we count for each image. 
(see example in the supplementary Fig S2). 
The program applies a constant threshold for pixel intensity to quantify cell diameter among 
four genotypes in an unbiased manner. Results from the analysis program were reviewed and 
minimally hand curated to avoid artifacts (false negative cells) and to make sure that if 
neurons did shrink in size, they did not fall below a certain area to be counted. For all studies, 
the experimenter was blind to the genotype of the mice. 
 
Statistical Analyses  
All data are expressed as the mean ± SEM. Variances between two groups were 
compared by F test and differences between two groups by unpaired Student's t test (two-
tailed, unless indicated otherwise in the figure legends). Differences among multiple groups 
were assessed by one-way or two-way ANOVA, followed by Tukey multiple comparisons 
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post-hoc tests, as specified in the figure legends. Correlations were assessed by linear 
regression and Spearman's correlation. Null hypotheses were rejected at p< 0.05. All 
statistical analysis was performed using Prism (Graphpad, GraphPad Prism v6.0; GraphPad 
Software La Jolla, CA). 
To address concerns related with winner’s curse on our data, we presented a very 
common summary statistic, Cohen’s d, whose single value can be plugged directly into 
standard statistical software (such as R, SAS, SPSS, STATA) or online sample size 
calculators (http://www.danielsoper.com/statcalc3/calc.aspx?id=47) to calculate the required 
sample size. If readers want to address issues of potential upward bias of the effect size, they 
could scale the estimate of the Cohen’s d by say 30% and then use this smaller effect size to 
calculate the necessary sample size (Supplementary Tables S1-S5). 
 
3.3. Results 
 
3.3.1. αB-Crystallin levels decrease over time in BACHD mice 
 
Sequestering chaperones into aggregates decreases the number of soluble chaperones 
that are available in the cell, and this presumably enhances abnormal protein folding (20). 
Levels of αBc and other chaperones decrease in the brains of an exon1 fragment HD model 
(29). Although mHtt exon1 is sufficient to cause disease, it lacks features of full-length Htt, 
such as post-translational modification sites, and protein interaction or signaling domains that 
may be important for regulating Htt proteostasis and toxicity. We wanted to determine if a 
decrease in endogenous αBc levels is altered during the progression of disease in the full-
length mouse model of HD – BACHD mice. This model shows a robust phenotypic 
behavioral deficit and neuropathological features, and full-length mHtt expression with 97 
polyQ is governed by the human Htt promoter, and so, it presumably recapitulates any cell- 
and time-dependent expression patterns seen in humans (44). 
Whole-brain lysates from BACHD mice and wild type (WT) littermates from 3, 6, 9 
and 12 months, corresponding to early- and late-onset stages of disease, were harvested. At 3 
and 6 months of age, the protein levels of αBc were not different in BACHD and WT mice. 
However, at 9 and 12 months of age, BACHD mice had significantly lower brain levels of 
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αBc than WT littermates (Fig. 1). The decreased protein levels of αBc over time in BACHD 
mice, especially after 6 months, correspond to the period where the behavioral and motor 
deficits in BACHD mice begin to be clearly detected (21). These data raise the possibility that 
a decline in αBc protein levels is involved in mediating pathogenesis. 
 
Figure 1. αB-crystallin levels decrease over time in BACHD mice. (A,B) BACHD (n=5) and WT 
(n=5) littermates were sacrificed at 3, 6, 9 and 12 months of age. Protein levels of αBc were 
determined by western blot analysis with whole-brain homogenates of BACHD and WT mice. 
(A) Immunoblots showing αBc protein level is decreased in BACHD, in an age-dependent manner, 
specifically after 6 months (when the motor symptoms are more robust in this mice model). (B) 
Respective quantifications of protein levels of αBc normalized to anti-β-tubulin (to show relative 
loading levels). Error bars represent standard errors of the mean (Means ± SEM). Data were tested for 
statistically significant differences using t-tests (*=p<0.05; **=p<0.01).  
 
3.3.2. Over-expression of αBc in astrocytes improves motor performance in 
BACHD mice 
 
To determine if the decline in αBc levels is an incidental finding or is playing a role in 
disease progression in BACHD mice, we sought to overexpress αBc and determine if it 
affected disease-associated phenotypes. To do so, we crossed BACHD mice with transgenic 
	  	   55	  
mice expressing the WT αBc gene, Cryab. Since aBc is predominantly expressed in glia, we 
chose a model in which Cryab is under the control of the human GFAP promoter that targets 
expression to astrocytes (26). We evaluated motor behaviors at 3, 7, 10 and 13 months of age. 
These ages in mice correspond to early-, mid- and late-stage disease with regard to 
symptomatology and neuropathology (34). Deficits in rotarod latency to fall (34, 45) and 
balance beam latency to cross (38, 46) were previously reported in BACHD. In these assays, 
BACHD mice had performance deficits in an age-dependent manner (Fig. 2). In our study, 
BACHD behavioral deficits were detected as early as 3 months of age in rotarod and balance 
beam tests. BACHD mice fall off an accelerating rotarod sooner than WT littermates and 
Cryab Tg mice (significant at 3, 7, 10 and 13 months), and this effect is partially rescued by 
astrocytic over-expression of the Cryab transgene in BACHD mice (double transgenic, DTg) 
at all time points tested (Fig. 2A).  
During the balance beam evaluation, the mice cohort was tested with a large-sized and 
a medium-sized balance beam (37). For our analyses, we used the data from the medium 
beam, which requires more motor coordination to cross than the large beam. BACHD mice 
took significantly more time to cross the medium beam than WT and Cryab Tg mice at 3, 7, 
10 and 13 months (Fig. 2B). αBc over-expression rescues this phenotype in BACHD only at 
the 7 months; therefore, αBc does not improve the overall latency to cross the balance beam 
of the BACHD mice (Fig. 2B). We also tested the ability to stay on the beam by measuring 
the number of slips and falls. DTg mice were significantly better on the medium beam than 
BACHD with fewer slips (Fig. 2C) and falls (Fig. 2D) at later stages of disease progression. 
The number of slips and falls of Cryab Tg mice was similar to WT mice (Fig. 2C,D). These 
results indicate a specific genetic interaction of αBc and mhtt that mediates the onset and 
severity of motor deficits in BACHD mice as measured by balance beam and rotarod assays.  
We found that BACHD and DTg mice gain significantly more weight (an average of 
20–30%) than WT and Cryab Tg controls, between 3 and 7 months until 13 months of age 
(Fig. 3). Since weight could affect motor performance, we examined the relationship of 
weight and rotarod and balance beam performance in BACHD mice. We found that the 
rotarod and balance beam performance in this cohort of BACHD and DTg mice at 3, 7, 10 
and 13 months was not significantly correlated with body weight (Fig. 4). Therefore, the 
improvement seen in the DTg is not explained by weight differences or the effect of weight 
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on motor performance. Thus, we conclude that astrocytic αBc positively affects BACHD 
motor performance. 
 
 
 
Figure 2. αBc overexpression improves behavioral readouts in BACHD mice. 
Behavioral readouts of disease progression in BACHD were measured at 3, 7, 10 and 13 months of 
age using rotarod and balance beam. Data at each time point were tested for statistically significant 
differences using two-way ANOVA with multiple comparisons tests corrected by Tukey post-hoc tests. 
At 3 months of age, group sizes were as follows: WT (n=20), Cryab Tg (n=19), BACHD (n=14), DTg 
(n=17). Values are means ± SEM. * = p <0.05, ** = p <0.01 or ***= <0.001 for main effect of the 
BACHD transgene by two-way ANOVA. (A) Rotarod. BACHD mice fall off an accelerating rotarod 
sooner than WT littermates and Cryab tg mice (significant main effect of the BACHD transgene). αBc 
over-expression partially rescues the BACHD motor impairment on DTg mice, and this is significant 
at all different time points at 3, 7, 10 and 13 months. (B) BACHD mice take significantly more time to 
cross the balance beam than WT littermates and Cryab tg mice. (C-D) The BACHD group also 
showed significant higher number of slips and falls during this task. αBc over-expression reduces the 
number of slips (C) and falls (D) in BACHD mice during the balance beam test. αBc overexpression 
does only change the overall latency to cross in DTg mice at 7 months, however, reduces significantly 
the number of slips (7, 10 and 13 months) and falls (10 and 13 months) of BACHD mice in the 
balance beam transversal assay.  
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Figure 3. DTg mice display the obesity-with-age phenotype seen in BACHD mice. Monthly 
weight measurements of the cohort of WT (n=20), Cryab Tg (n=19), BACHD (n=14), and DTg (n=17) 
mice, prior to the initiation of behavioral testing at each time-point. The body weight of DTg mice is 
not different from BACHD mice. Data were analyzed by two-way repeated measures ANOVA 
followed by comparisons of the means with Tukey post-hoc tests. 
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Figure 4. BACHD and DTg mice body weight phenotype does not correlate with their motor 
performance. The correlation between body weight and rotarod and balance beam performance in 
BACHD (n=12) and DTg mice (n=16) was examined. Correlations graphs for BACHD and DTg 
groups are in the left and right panel, respectively.  
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(A) Body weight correlation with latency to fall in rotarod at 13 months.  
(B) Body weight correlation with latency to cross the balance beam at 7 months (only time point 
BACHD and DTg were significantly different).  
(C) Body weight correlation with number of falls in balance beam at 13 months. 
(D) Body weight correlation with number of slips in balance beam at 13 months 
Our data indicate that the rotarod and balance beam BACHD and DTg mice motor performance is not 
correlated with their higher body weight at any time point (data not shown for 3, 7, 10 months). 
Therefore, the improvement seen in the DTg compared to the BACHD is not explained by weight 
differences or the effect of weight on motor performance. Data were analyzed by using the 
nonparametric Spearman correlation coefficient. 
 
3.3.3. Expression of αBc in astrocytes improves strategy shifting in BACHD 
mice  
In addition to motor performance, BACHD mice also exhibit cognitive decline at a 
later stage of the disease (47, 48), similar to what is observed in HD patients (49, 50). 
Therefore, we wanted to examine the effect of αBc over-expression on cognitive performance 
in a sensitive striatal learning-dependent assay, the swimming T-maze test. We used this test 
to measure procedural and spatial learning in symptomatic BACHD at the last time point of 
behavioral evaluation, when the mice were 13 months of age (a time known for more 
accentuated neurobehavioral dysfunction and cognitive decline in BACHD mice). The test 
was performed at only one time point in the course of disease progression to avoid any bias 
related to recall or long-term memory of the task. This task was previously tested in a 
different mouse model of full-length Htt, YAC128 mice, as a simple two-choice test of striatal 
dependent- learning and memory to facilitate rapid training and testing in visually cognitive-
impaired mice (39). A schematic representation of the water T-maze task is presented in Fig. 
5A. Briefly, on the first day, the mice were trained to swim and enter the correct arm on the 
T-maze, where a hidden platform was placed (right or left to avoid side biases). Upon 
reaching the platform, which completes the task, mice are rewarded by being allowed to 
return to their cages. Every day consisted of three trials. During normal phase swimming (i.e., 
days 2–7), the mice from all groups learned the task and made more correct choices over the 
course of the test (Fig. 5A). We observed no difference among genotypes performing the task 
during the 7-day trial. Thus, the BACHD and DTg groups learned to find the platform similar 
to their control littermates (Fig. 5B). The time to reach the platform (Fig. 5D), the swim 
velocity and the distance taken to reach the platform were not different among groups. 
 To assess the ability of BACHD mice to change strategy, we incorporated a reversal 
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phase into the swimming T-maze test by switching the platform to the opposite arm of the 
maze. Mice that were trained to swim directly to the right or left arm would now have to 
change their strategy to find the shortest path to the platform. WT, Cryab Tg and DTg mice 
swam down the arm they were trained initially, and after discovering that the platform was no 
longer present, immediately swam down the unvisited opposite arm of the maze and found the 
platform. Similar to the WT mice, all of the BACHD mice entered the arm of the T-maze they 
initially trained to. However, after discovering that the platform was not present in the 
opposite arm of the maze, the majority of the BACHD mice swam back to the start of the T-
maze where they had already been. We measured this abnormality by quantifying the number 
of arms of the maze entered en route to the platform. This pattern of response resulted in the 
BACHD mice having more arm entries than WT, Cryab Tg and DTg mice, as it was 
apparently more difficult for the BACHD group to attain the 50% correct arm entries in the 
reversal arm over the course of the test (Fig. 5C). These results are consistent with findings 
observed in HD patients: during a re-learning process, HD patients tend to perseverate and 
have more difficulties in strategy-shifting, than healthy subjects (51–57). The difference 
between the number of correct entries of the BACHD group was significantly lower (below 
50%) than in the DTg group from day 3 to day 5 in the reversal test. In addition, DTg mice 
took significantly less time to relocate the hidden platform (Fig. 5E) than BACHD mice. DTg 
mice were not different from the WT and Cryab Tg groups.  
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Figure 5. αBc over-expression improves BACHD strategy shifting in the water-T maze test. 
(A) Water-T maze test diagram. BACHD mice were tested in the swimming T-maze with reversal. At 
13 months of age, group sizes were as follows: WT (n=18), Cryab Tg (n=17), BACHD (n=10), DTg 
(n=15). Symptomatic BACHD show cognitive deficits in strategy shifting, and αBc overexpression 
rescues this impairment. (B) During the normal phase of the test, the four distinct groups learned to 
swim to the platform, and no differences were observed in the percentage of correct arm entries, 
having the four groups reaching ≥ 80% of correct entries, and (D) in the time to reach the platform. 
(C) During the reversal phase, when the location of the platform was switched, BACHD mice showed 
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a significant lower number of correct entries in the reversal arm and (E) required significantly more 
time to find the platform than the other groups from day 3 to day 5. Speed (cm/s) and distance (cm) to 
locate the platform in either training and reversal phases was not different among the four genotypes 
during this test performance. A two-way Anova was performed, with multiple comparisons tests, 
corrected by Tukey Test. *=p< 0.05. 
 
3.3.4. αB-crystallin overexpression modulates levels of mhtt and inclusion body 
formation BACHD mice 
 
To determine if the improved motor and cognitive behavioral phenotypes in DTg mice 
correlated with neuropathological changes, we examined disease features, such as inclusion 
body (IB) formation and neuronal cell loss. IB formation with mhtt is a hallmark of HD 
pathology. Aged BACHD mice develop IBs that are similar to those in the human disease and 
can be visualized histologically with specific htt antibodies. We examined serial sections from 
cortex and caudate-putamen/ striatum of 13-month-old mice of this cohort and observed 
differences in the density or size of inclusion bodies. Staining with the polyclonal antibody 
S830, which selectively recognizes expanded mhtt (34, 58), revealed prominent IBs in both 
the cortex and striatum of BACHD and DTG but not WT and Cryab Tg mice, as expected 
(Fig. 6C,D). Although there is a trend for a decrease of IB numbers in DTG when compared 
to BACHD, this difference did not reach statistical significance. However, there were 
significantly fewer larger inclusions (>1 µm) in DTg mice than in BACHD mice (Fig. 6D), 
indicating an overall reduction in size of inclusions. 
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Figure 6. αBc over-expression decreases soluble levels of mutant huntingtin and reduces the size 
of S830 inclusion bodies in BACHD mice. 
(A) Representative western blot of WT, Cryab Tg, DTg and BACHD (n=4) cortical lysates with 
4H7H7 and anti-β-tubulin as a loading control and (B) subsequent quantification of signal intensity. 
Values are based on the mean of three independent 4H7H7 blots of four mice per group compared 
across different blots. All value were first normalized for input using the anti-β-tubulin controls. (C) 
Immunohistochemistry with polyoclonal S830 revealed prominent immunoreactive inclusion bodies in 
BACHD and DTg mice cortex and striatum but not in the WT and Cryab Tg littermate controls (data 
not shown). S830 immunohistochemistry in (a, c) BACHD and (b, d) DTg representative mouse 
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brains with average levels of aggregate counts and density for the two groups: (a,b) M1/M2 cortex 
layer III and (c,d) striatum/medial caudate/putamen, using Renyi/Entropy threshold and >1µm 
diameter. The scale bar represents 100 µm and the field size is 205 µm X 150µm. (D) The number of 
mHtt nuclear inclusions >1 µm were significantly reduced in the DTg when compared to BACHD 
mice. Values are means±SD; BACHD (n=9) and DTg (N=6), *=p< 0.05 by Student’s unpaired t-test. 
 
The difference in IBs mediated by αBc suggested that other features of mHtt 
proteostasis might also be altered. Since expression level of mHtt is a strong predictor of 
neurodegeneration in polyQ transfected rodent primary neurons (59, 60) and correlated with 
deficits in HD animal models (44), we compared the steady-state levels of soluble mHtt in 
cortical lysates. 
Using the mouse monoclonal antibody 4H7H7, which preferentially recognizes 
pathogenic polyQ stretches (61), we found that DTg mice have a modest but reproducible and 
statistically significant reduction in soluble mHtt protein, compared to levels in BACHD mice 
(Fig. 6 A,B). Similar results were found with the mouse monoclonal antibody 1C2, selective 
for mHtt, in which a small but reproducible and significant decrease in soluble mHtt protein 
of the DTg mice when compared to BACHD mice (data not shown). In summary, these 
results suggest that αBc is involved in modulating mHtt protein levels and mHtt IB size, two 
prominent hallmarks of HD pathogenesis. 
 
3.3.5. αB-crystallin overexpression prevents cortical and striatal 
neurodegeneration caused by the expression of mHtt in BACHD mice 
 
Pathological examination of brains of HD patients reveals profound atrophy and cell 
death of medium spiny neurons (MSNs) of the striatum, with cortical loss also a feature as the 
disease progresses (4). BACHD mice present intranuclear inclusions and also show selective 
degeneration of the MSNs, in addition to significant atrophy of the forebrain without 
accompanying changes in the cerebellum (34), similar to the pattern of degeneration in human 
HD (62, 63). 
Having found that αBc overexpression improves both motor and cognitive-like 
phenotypes in BACHD mice and may help reduce the levels of the mHtt protein, we next 
sought to determine if the overexpression of αBc influences other neuropathological features 
of disease, looking at the striatum and cortex atrophy and/or cell loss. In BACHD brains at 
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late stage of disease (13 months of age), more than 95% of MSNs express dopamine and 
cyclic AMP-regulated protein (32 kDa, also known as DARPP-32) (64). We have used a 
sophisticated system for quantitative immunofluorescence and morphometry to measure the 
expression of striatal spiny neuron–specific protein, DARPP-32, in BACHD, DTg, Cryab Tg 
and WT mice (Fig. 7A, B). We found fewer DARPP-32+ cells in BACHD striatum than in 
the other genotypes. In the DTg mice, the number of DARPP-32+ cells was similar to those 
on WT and Cryab Tg mice (Fig. 7A, B).  
Although HD is predominantly associated with degeneration of the striatum, it also 
involves cortical areas (30). To measure striatal and cortical neuronal cell loss, we stained 
brain sections with the NeuN antibody, which recognizes neuron-specific nuclear protein (Fig. 
7C–F). We observed a significant decrease of both striatal (Fig. 7 C,D) and cortical (Fig. 7 
E,F) NeuN+ counts when compared to WT mice, Cryab Tg and DTg mice. Taken together, 
our results indicate that astrocytic expression of αBc is associated with a significant reduction 
in striatal and cortical neuropathology in the BACHD model. Given that astrocytic 
overexpression of αBc significantly mitigates pathology in neurons, it further suggests that 
αBc overexpression may be acting in a non-cell autonomous manner. 
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Figure 7. αBc over-expression rescues the neurodegeneration caused by expression of full-length 
mutant huntingtin at 13 months of age in BACHD.  
Measurement of striatal DARPP-32-positive cells and striatal cortical NeuN-positive cells in a: WT 
(n=5), b: Cryab Tg (n=5), c: BACHD (n=8), d: DTg (n=7).  
(A) Representative confocal micrographs of DARPP-32 immunostaining and (B) DARPP-32 positive 
cells quantification plots. (C,E) Representative confocal micrographs of NeuN immunostaining in the 
striatum/medial caudate/putamen (C) and M1/M2 cortex (E), followed by NeuN-positive cells 
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quantification plots (D, F). Each field is 600 x 600 µm, and the scale bar represents 20 µm. Values 
represent means ± SEM. *p < 0.05, one-way ANOVA with multiple Tukey multiple comparisons 
correction. 
 
3.4. Discussion 
No therapeutics directly and effectively target and remediate the protein-misfolding 
events and selective neuronal vulnerability associated with many devastating 
neurodegenerative disorders (65). Therefore, approaches that target molecular chaperones 
may be beneficial in protein conformational diseases. 
In the present study, we report for the first time the effect of the sHsp αB-crystallin 
(αBc) in a full-length mHtt model, the BACHD mouse. Expression of αBc in astrocytes 
improved the motor (RotaRod and Balance Beam) and cognitive performance (Water-T-
maze) of the BACHD mice, as well as neuropathological features associated with HD. Overall, 
our data indicate that modulating the levels of αBc protect against the progression of HD. 
We hypothesize that αBc has an important modulatory role during HD since the ability 
to effectively initiate the heat shock response (HSR), and other homeostatic cellular pathways 
(e.g., apoptosis, oxidative stress) in which αBc functions, are compromised during HD disease 
progression (66). We should also take into account, as a chaperone with multi-functional 
capabilities, αBc may alleviate stress by promoting ubiquitin/proteasomal degradation of 
corrupt proteins (67, 68) preventing apoptosis (69–72) or by stabilizing intermediate filaments 
and the cytoskeleton integrity (73, 74). 
The most obvious candidate mechanism for chaperone-mediated rescue of HD 
neurotoxicity is inhibiting or reversing Htt aggregate (fibrils/polymers) formation. Although 
mHtt is expressed in glial cells, the neuronal population contains most of mHtt aggregates (4, 
75). Our results indicate that αBc modulates mHtt levels and the features of IBs in a typical 
chaperone manner. Interestingly, however, the effect of this chaperone is via overexpressing 
αBc in astrocytes. Overexpression of chaperones may reduce large IBs by preventing 
oligomer formation, and oligomeric precursors may be the most toxic species (6, 76, 77). As 
with most Hsps, sHps can also be important for protein stability and protein turnover. 
Evidence suggests that affinity of αBc for its chaperone substrates is modulated by its 
chaperone oligomerization status and the functional structure of αBc is a dimer, which results 
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from interactions of β-strands in the α-crystallin domain (78, 79). Since the binding capacity 
can reach one substrate protein per sHsp subunit, big chaperone oligomer structures (via sHsp 
oligomerized complexes) are major contributors to the chaperoning capacity of the cell. It 
remains unclear how the decision to refold or degrade a misfolded protein is made. Some 
small sHsps (αBc and Hsp27) interact directly or indirectly with the proteasome and form part 
of ubiquitin ligase complexes (αBc and HspB10) that are involved in the proteasomal 
degradation of certain proteins in a quite selective manner under stress conditions (80). Thus, 
αBc could regulate mHtt protein levels by stabilizing mHtt in IBs or by promoting misfolded 
mHtt refolding with the cooperative help of other chaperone complexes, namely the 
Hsp70/Hsp40 machinery, as well as targeting it for proteosomal degradation. 
But how could astrocytic αBc mediate this effect on neuronal aggregation and mhtt 
levels? αBc is secreted in exosomes under a variety of stress-related conditions (81). One 
possible mechanism of modulating neuronal IBs could be through αBc-mediated extracellular 
signaling from astrocytes to neurons. There is emerging evidence that astrocyte-derived 
exosomes carry neuroprotective cargo and could contribute to neuronal survival (82). 
Exosomes may execute their functions by distinct modes of action: (1) internalization by 
target cells and cargo retrieval, (2) binding to the cell surface and triggering second messenger 
pathways, and (3) release of components into the extracellular matrix. However, their 
interaction as well as their protein content with target cells is not well understood at a 
mechanistic level (82). A study using retinal pigment epithelial (RPE) cells (83) showed that 
an increased uptake of exogenous αBc and protection from oxidative stress and apoptosis by 
inhibition of caspase-3 and PARP activation were observed in stressed RPE cultures. In this 
manner, we speculate that exosomes containing αBc could protect both glia and neuronal 
population in BACHD from mhtt-derived toxicity, as activation of caspase-3 and oxidative 
stress. Future studies will be necessary to test this hypothesis. 
In our BACHD model, we additionally observed that astrocytic αBc overexpression 
resulted in protection of medium spiny neurons in the striatum, as well as cortical neurons. 
This rescue effect of astrocytic αBc on neurons further suggests that αBc confers 
neuroprotection in a non-cell-autonomous manner. The vast range of astrocytic functions, 
such as maintaining homeostasis at the synapse, regulating neuronal signaling, protecting 
neurons from oxidative damage, and glutamate uptake, may have wide-ranging implications 
	  	   69	  
for the pathogenesis of protein aggregation disorders (84, 85). HD, PD, spinocerebellar ataxia 
and ALS all demonstrate non-cell-autonomous pathology in which glial expression of mutant 
proteins has a toxic effect on vulnerable neurons, suggesting this may be a common feature of 
neurodegenerative disorders (86). In addition, a marked decreased expression of both 
glutamate transporters, GLAST and GLT-1, and of glutamate uptake, in a HD mouse model, 
were associated with neuronal dysfunction as observed by a reduction of the DARPP-32 and 
NR2B expression (31). Also, viral delivery of potassium channels (Kir4.) to striatal astrocytes 
restored Kir4.1 function, normalized extracellular K(+), ameliorated aspects of MSN 
dysfunction, prolonged survival and attenuated some motor phenotypes in R6/2 mice (32). 
These studies together may suggest astrocytes and ion channels and astrocytic-mediated 
transport as therapeutic targets. Interestingly, αBc over- expression was shown to maintain 
astrocyte functions such as glutamate uptake in Alexander Disease mouse model (26) 
however we could not observe the same result in the BACHD mice. Further studies will be 
necessary to test αBc over- expression in astrocytic-mediated ion transport and ion channels 
expression in HD. 
Co-culture of neurons with astrocytes from WT or BACHD mice identified mutant 
astrocytes as a source of adverse non-cell autonomous effects on neuron energy metabolism 
possibly by increasing oxidative stress (33). Therefore, BACHD astrocytes may fail to 
provide adequate metabolic support to neurons. As αBc overexpression in astrocytes is 
sufficient to protect BACHD neurons in our study, it is possible that αBc is helping to restore 
metabolic support in astrocytes (e.g., antioxidant protection and glucose uptake) in DTg mice, 
protecting the neighboring neuronal population from mHtt-derived toxicity. Also, the 
chaperoning ability of αBc could be functioning to restore dysfunctional proteostasis in a 
general manner in astrocytes, leading to improvement in astrocyte health and astrocyte-to-
neuron signaling. Overall, our studies indicate that astrocyte-mediated neuronal protection 
could be an important component of a therapeutic strategy for HD and other degenerative 
disorders with glial involvement. 
In summary, our findings show that elevation of αBc in astrocytes may protect 
vulnerable neurons from mHtt toxicity, which could lead to improvements in motor behavior 
and cognition, as well as protecting against neuropathological deficits during BACHD disease 
progression. Our data are consistent with the possibility that metabolic deficiency in HD 
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astrocytes plays a significant role in disease progression. Restoration of this deficiency by 
chaperones, such as αBc, may represent a potential mechanism of neuroprotection. Although 
the precise mechanism by which αBc overexpression alleviates neurodegeneration in BACHD 
is not fully understood, future studies will help to unravel the function of αBc in complex 
interactions with mHtt and potential other stressor targets in HD.  
 
3.5. References 
1. Landles,C. and Bates,G.P. (2004) Huntingtin and the molecular pathogenesis of Huntington’s disease. Fourth 
in molecular medicine review series. EMBO Rep., 5, 958–63. 
2. Finkbeiner,S. (2011) Huntington ’ s Disease. Cold Spring Harb. Perspect. Biol., 3, 1–24. 
3. Gil,J.M. and Rego,A.C. (2008) Mechanisms of neurodegeneration in Huntington’s disease. Eur. J. Neurosci., 
27, 2803–20. 
4. Vonsattel, Jean Paul,D.M. (1998) Hungtington’s disease. J. Neuropathol. Exp. Neurol. 
5. Lindquist,S. (1986) THE HEAT-SHOCK RESPONSE. Ann. Rev. Biochem., 55, 1151–91. 
6. Muchowski,P.J. and Wacker,J.L. (2005) Modulation of neurodegeneration by molecular chaperones. Nat. Rev. 
Neurosci., 6, 11–22. 
7. Wyttenbach,A. (2004) Role of Heat Shock Proteins During Polyglutamine Neurodegeneration. J. Mol. 
Neurosci., 23, 69–95. 
8. Wyttenbach,A., Carmichael,J., Swartz,J., Furlong,R.A., Narain,Y., Rankin,J. and Rubinsztein,D.C. (2000) 
Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in 
cellular models of Huntington’s disease. Proc. Natl. Acad. Sci. U. S. A., 97, 2898–2903. 
9. Vos,M.J., Zijlstra,M.P., Kanon,B., van Waarde-Verhagen,M. a W.H., Brunt,E.R.P., Oosterveld-Hut,H.M.J., 
Carra,S., Sibon,O.C.M. and Kampinga,H.H. (2010) HSPB7 is the most potent polyQ aggregation 
suppressor within the HSPB family of molecular chaperones. Hum. Mol. Genet., 19, 4677–93. 
10. Warrick,J.M., Chan,H.Y., Gray-Board,G.L., Chai,Y., Paulson,H.L. and Bonini,N.M. (1999) Suppression of 
polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat. Genet., 
23, 425–8. 
11. Garrido,C., Paul,C., Seigneuric,R. and Kampinga,H.H. (2012) The small heat shock proteins family: the long 
forgotten chaperones. Int. J. Biochem. Cell Biol., 44, 1588–92. 
12. Hayes,D., Napoli,V., Mazurkie,A., Stafford,W.F. and Graceffa,P. (2009) Phosphorylation dependence of 
Hsp27 multimeric size and molecular chaperone function. J. Biol. Chem., 284, 18801–18807. 
13. Robertson,A.L., Headey,S.J., Saunders,H.M., Ecroyd,H., Scanlon,M.J., Carver,J. a and Bottomley,S.P. 
(2010) Small heat-shock proteins interact with a flanking domain to suppress polyglutamine aggregation. 
Proc. Natl. Acad. Sci. U. S. A., 107, 10424–9. 
14. Carver,J.A., Rekas,A., Thorn,D.C. and Wilson,M.R. (2003) Review Article Small Heat-shock Proteins and 
Clusterin  : Intra- and Extracellular Molecular Chaperones with a Common Mechanism of Action and 
Function  ? IUBMB Life, 55, 661–668. 
15. Ecroyd,H. and Carver,J. a (2009) Crystallin proteins and amyloid fibrils. Cell. Mol. Life Sci., 66, 62–81. 
16. Westerheide,S.D. and Morimoto,R.I. (2005) Heat shock response modulators as therapeutic tools for diseases 
of protein conformation. J. Biol. Chem., 280, 33097–100. 
17. Muchowski,P.J., Schaffar,G., Sittler, a, Wanker,E.E., Hayer-Hartl,M.K. and Hartl,F.U. (2000) Hsp70 and 
hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc. Natl. 
Acad. Sci. U. S. A., 97, 7841–6. 
18. Satyal,S.H., Schmidt,E., Kitagawa,K., Sondheimer,N., Lindquist,S., Kramer,J.M. and Morimoto,R.I. (2000) 
Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proc. Natl. Acad. 
Sci. U. S. A., 97, 5750–5. 
19. Jana,N.R., Tanaka,M., Wang,G.H. and Nukina,N. (2000) Polyglutamine length-dependent interaction of 
Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of 
	  	   71	  
aggregation and cellular toxicity. Hum. Mol. Genet., 9, 2009–2018. 
20. Hay,D.G., Sathasivam,K., Tobaben,S., Stahl,B., Marber,M., Mestril,R., Mahal,A., Smith,D.L., Woodman,B. 
and Bates,G.P. (2004) Progressive decrease in chaperone protein levels in a mouse model of Huntington’s 
disease and induction of stress proteins as a therapeutic approach. Hum. Mol. Genet., 13, 1389–1405. 
21. Horwitz,J. (2003) Alpha-crystallin. Exp. Eye Res., 76, 145–153. 
22. Rekas,A., Adda,C.G., Andrew Aquilina,J., Barnham,K.J., Sunde,M., Galatis,D., Williamson,N. a, 
Masters,C.L., Anders,R.F., Robinson,C. V, et al. (2004) Interaction of the molecular chaperone alphaB-
crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity. J. Mol. Biol., 
340, 1167–83. 
23. Waudby,C. a., Knowles,T.P.J., Devlin,G.L., Skepper,J.N., Ecroyd,H., Carver,J. a., Welland,M.E., 
Christodoulou,J., Dobson,C.M. and Meehan,S. (2010) The interaction of αB-crystallin with mature α-
synuclein amyloid fibrils inhibits their elongation. Biophys. J., 98, 843–851. 
24. Hochberg,G.K. a, Ecroyd,H., Liu,C., Cox,D., Cascio,D., Sawaya,M.R., Collier,M.P., Stroud,J., Carver,J. a, 
Baldwin,A.J., et al. (2014) The structured core domain of αB-crystallin can prevent amyloid fibrillation 
and associated toxicity. Proc. Natl. Acad. Sci. U. S. A., 111, E1562-70. 
25. Wang,J., Xu,G., Li,H., Gonzales,V., Fromholt,D., Karch,C., Copeland,N.G., Jenkins,N. a. and Borchelt,D.R. 
(2005) Somatodendritic accumulation of misfolded SOD1-L126Z in motor neurons mediates degeneration: 
αB-crystallin modulates aggregation. Hum. Mol. Genet., 14, 2335–2347. 
26. Hagemann,T.L., Boelens,W.C., Wawrousek,E.F. and Messing,A. (2009) Suppression of GFAP toxicity by 
alphaB-crystallin in mouse models of Alexander disease. Hum. Mol. Genet., 18, 1190–9. 
27. Muchowski,P.J., Ramsden,R., Nguyen,Q., Arnett,E.E., Greiling,T.M., Anderson,S.K. and Clark,J.I. (2008) 
Noninvasive measurement of protein aggregation by mutant huntingtin fragments or alpha-synuclein in the 
lens. J. Biol. Chem., 283, 6330–6. 
28. Tue,N.T., Shimaji,K., Tanaka,N. and Yamaguchi,M. (2012) Effect of alphaB-crystallin on protein 
aggregation in drosophila. J. Biomed. Biotechnol., 2012. 
29. Zabel,C. (2002) Alterations in the Mouse and Human Proteome Caused by Huntington’s Disease. Mol. Cell. 
Proteomics, 1, 366–375. 
30. Ehrlich,M.E. (2012) Huntington’s disease and the striatal medium spiny neuron: cell-autonomous and non-
cell-autonomous mechanisms of disease. Neurotherapeutics, 9, 270–84. 
31. Faideau,M., Kim,J., Cormier,K., Gilmore,R., Welch,M., Auregan,G., Dufour,N., Guillermier,M., Brouillet,E., 
Hantraye,P., et al. (2010) In vivo expression of polyglutamine-expanded huntingtin by mouse striatal 
astrocytes impairs glutamate transport: A correlation with Huntington’s disease subjects. Hum. Mol. Genet., 
19, 3053–3067. 
32. Tong,X., Ao,Y., Faas,G.C., Nwaobi,S.E., Xu,J., Haustein,M.D., Anderson,M. a, Mody,I., Olsen,M.L., 
Sofroniew,M. V, et al. (2014) Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in 
Huntington’s disease model mice. Nat. Neurosci., 17, 694–703. 
33. Boussicault,L., Hérard,A.-S., Calingasan,N., Petit,F., Malgorn,C., Merienne,N., Jan,C., Gaillard,M.-C., 
Lerchundi,R., Barros,L.F., et al. (2014) Impaired brain energy metabolism in the BACHD mouse model of 
Huntington’s disease: critical role of astrocyte-neuron interactions. J. Cereb. Blood Flow Metab., 23, 1–11. 
34. Gray,M., Shirasaki,D.I., Cepeda,C., André,V.M., Wilburn,B., Lu,X.-H., Tao,J., Yamazaki,I., Li,S.-H., 
Sun,Y.E., et al. (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit 
progressive and selective neuropathogenesis in BACHD mice. J. Neurosci., 28, 6182–95. 
35. Hagemann,T.L., Boelens,W.C., Wawrousek,E.F. and Messing,A. (2009) Suppression of GFAP toxicity by 
aB-crystallin in mouse models of Alexander disease. 18, 1190–1199. 
36. Lister,R.G. (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl)., 92, 
180–185. 
37. Larkin, Paul B., Muchowski,P.J. (2012) Genetic Deficiency of Complement Component 3 Does Not Alter 
Disease Progression in a Mouse Model of Huntington’s Disease. J. Huntingtons. Dis., 29, 997–1003. 
38. Bouchard,J., Truong,J., Bouchard,K., Dunkelberger,D., Desrayaud,S., Moussaoui,S., Tabrizi,S.J., Stella,N. 
and Muchowski,P.J. (2012) Cannabinoid receptor 2 signaling in peripheral immune cells modulates 
disease onset and severity in mouse models of Huntington’s disease. J. Neurosci., 32, 18259–68. 
39. Van Raamsdonk,J.M., Pearson,J., Slow,E.J., Hossain,S.M., Leavitt,B.R. and Hayden,M.R. (2005) Cognitive 
dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of 
Huntington’s disease. J. Neurosci., 25, 4169–80. 
40. Taketo,M., Schroeder, a C., Mobraaten,L.E., Gunning,K.B., Hanten,G., Fox,R.R., Roderick,T.H., 
Stewart,C.L., Lilly,F. and Hansen,C.T. (1991) FVB/N: an inbred mouse strain preferable for transgenic 
	  	   72	  
analyses. Proc. Natl. Acad. Sci. U. S. A., 88, 2065–2069. 
41. Osmand,A.P., Berthelier,V. and Wetzel,R. (2006) Imaging polyglutamine deposits in brain tissue. Methods 
Enzymol., 412, 106–22. 
42. Wellner,P.D. (1993) Adaptive thresholding for the DigitalDesk. Eur. Tech. Rep., 110, 1–17. 
43. Samsi,S., Lozanski,G., Shana’ah,A., Krishanmurthy,A.K. and Gurcan,M.N. (2010) Detection of follicles 
from IHC-stained slides of follicular lymphoma using iterative watershed. IEEE Trans Biomed Eng, 57, 
2609–2612. 
44. Slow,E.J., van Raamsdonk,J., Rogers,D., Coleman,S.H., Graham,R.K., Deng,Y., Oh,R., Bissada,N., 
Hossain,S.M., Yang,Y.Z., et al. (2003) Selective striatal neuronal loss in a YAC128 mouse model of 
Huntington disease. Hum. Mol. Genet., 12, 1555–1567. 
45. Menalled,L., El-Khodor,B.F., Patry,M., Suárez-Fariñas,M., Orenstein,S.J., Zahasky,B., Leahy,C., 
Wheeler,V., Yang,X.W., MacDonald,M., et al. (2009) Systematic behavioral evaluation of Huntington’s 
disease transgenic and knock-in mouse models. Neurobiol. Dis., 35, 319–36. 
46. Kwan,W., Träger,U., Davalos,D., Chou,A., Bouchard,J., Andre,R., Miller,A., Weiss,A., Giorgini,F., 
Cheah,C., et al. (2012) Mutant huntingtin impairs immune cell migration in Huntington disease. J. Clin. 
Invest., 122. 
47. Crook,Z.R. and Housman,D. (2011) Huntington’s disease: can mice lead the way to treatment? Neuron, 69, 
423–35. 
48. Abada,Y.-S.K., Nguyen,H.P., Ellenbroek,B. and Schreiber,R. (2013) Reversal learning and associative 
memory impairments in a BACHD rat model for Huntington disease. PLoS One, 8, e71633. 
49. Paulsen,J.S., Langbehn,D.R., Stout,J.C., Aylward,E., Ross,C.A., Nance,M., Guttman,M., Johnson,S., 
MacDonald,M., Beglinger,L.J., et al. (2008) Detection of Huntington’s disease decades before diagnosis: 
the Predict-HD study. J. Neurol. Neurosurg. Psychiatry, 79, 874–880. 
50. Paulsen,J.S., Ready,R.E., Hamilton,J.M., Mega,M.S. and Cummings,J.L. (2001) Neuropsychiatric aspects of 
Huntington ’ s disease. J Neurol Neurosurg Psychiatry, 5, 310–314. 
51. Hahn-Barma,V., Deweer,B., Durr,A., Dode,C., Feingold,J., Pillon,B., Agid,Y., Brice,A. and Dubois,B. 
(1998) Are cognitive changes the first symptoms of Huntington’s disease? A study of gene carriers. J. 
Neurol. Neurosurg. Psychiatry, 64, 172–177. 
52. Lawrence,A.D., Sahakian,B.J., Hodges,J.R., Rosser,A.E., Lange,K.W. and Robbins,T.W. (1996) Executive 
and mnemonic functions in early Huntington’s disease. Brain, 119, 1633–1645. 
53. Lawrence,A.D., Hodges,J.R., Rosser,A.E., Kershaw,A., Ffrench-Constant,C., Rubinsztein,D.C., 
Robbins,T.W. and Sahakian,B.J. (1998) Evidence for specific cognitive deficits in preclinical Huntington’s 
disease. Brain, 121, 1329–1341. 
54. Lawrence,A.D., Sahakian,B.J. and Robbins,T.W. (1998) Cognitive functions and corticostriatal circuits: 
Insights from Huntington’s disease. Trends Cogn. Sci., 2, 379–388. 
55. Snowden,J.S., Craufurd,D., Thompson,J. and Neary,D. (2002) Psychomotor, executive, and memory 
function in preclinical Huntington’s disease. J. Clin. Exp. Neuropsychol., 24, 133–145. 
56. Thompson,J.C., Ph,D., Harris,J., Sc,B., Sollom,A.C., Stopford,C.L., Howard,E., Snowden,J.S., Craufurd,D. 
and Sc,M. (2012) Longitudinal Evaluation of Neuropsychiatric Symptoms in Huntington ’ s Disease. J 
Neuropsychiatry Clin Neurosci. 
57. Snowden,J.S., Gibbons,Z.C., Blackshaw,A., Doubleday,E., Thompson,J., Craufurd,D., Foster,J., Happé,F. 
and Neary,D. (2003) Social cognition in frontotemporal dementia and Huntington’s disease. 
Neuropsychologia, 41, 688–701. 
58. Pouladi,M. a, Stanek,L.M., Xie,Y., Franciosi,S., Southwell,A.L., Deng,Y., Butland,S., Zhang,W., 
Cheng,S.H., Shihabuddin,L.S., et al. (2012) Marked differences in neurochemistry and aggregates despite 
similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and 
YAC128 mice. Hum. Mol. Genet., 21, 2219–32. 
59. Miller,J., Arrasate,M., Brooks,E., Libeu,C.P., Legleiter,J., Hatters,D., Curtis,J., Cheung,K., Krishnan,P., 
Mitra,S., et al. (2012) Identifying polyglutamine protein species in situ that best predict neurodegeneration. 
Nat. Chem. Biol., 8, 318–318. 
60. Miller,J., Arrasate,M., Shaby,B.A., Mitra,S., Masliah,E. and Finkbeiner,S. (2010) Quantitative relationships 
between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide 
novel insight into huntington’s disease molecular pathogenesis. J. Neurosci., 30, 10541–10550. 
61. Gu,X., Greiner,E.R., Mishra,R., Kodali,R., Osmand,A., Finkbeiner,S., Steffan,J.S., Thompson,L.M., 
Wetzel,R. and Yang,X.W. (2009) Serines 13 and 16 Are Critical Determinants of Full-Length Human 
Mutant Huntingtin Induced Disease Pathogenesis in HD Mice. Neuron, 64, 828–840. 
	  	   73	  
62. Gourfinkel-An,I., Vila,M., Faucheux,B., Duyckaerts,C., Viallet,F., Hauw,J.J., Brice,A., Agid,Y. and 
Hirsch,E.C. (2002) Metabolic changes in the basal ganglia of patients with Huntington’s disease: An in 
situ hybridization study of cytochrome oxidase subunit I mRNA. J. Neurochem., 80, 466–476. 
63. Herndon,E.S., Hladik,C.L., Shang,P., Burns,D.K., Raisanen,J. and White,C.L. (2009) Neuroanatomic profile 
of polyglutamine immunoreactivity in Huntington disease brains. J. Neuropathol. Exp. Neurol., 68, 250–
261. 
64. Ouimet,C.C., Langley-Gullion,K.C. and Greengard,P. (1998) Quantitative immunocytochemistry of DARPP-
32-expressing neurons in the rat caudatoputamen. Brain Res., 808, 8–12. 
65. Labbadia,J. and Morimoto,R.I. (2013) Huntington’s disease: Underlying molecular mechanisms and 
emerging concepts. Trends Biochem. Sci., 38, 378–385. 
66. Arrigo,A.P., Simon,S., Gibert,B., Kretz-Remy,C., Nivon,M., Czekalla,A., Guillet,D., Moulin,M., Diaz-
Latoud,C. and Vicart,P. (2007) Hsp27 (HspB1) and αB-crystallin (HspB5) as therapeutic targets. FEBS 
Lett., 581, 3665–3674. 
67. den Engelsman,J., Keijsers,V., de Jong,W.W. and Boelens,W.C. (2003) The small heat-shock protein alpha 
B-crystallin promotes FBX4-dependent ubiquitination. J. Biol. Chem., 278, 4699–704. 
68. Lin,D.I., Barbash,O., Kumar,K.G.S., Weber,J.D., Harper,J.W., Klein-Szanto,A.J.P., Rustgi,A., Fuchs,S.Y. 
and Diehl,J.A. (2006) Phosphorylation-Dependent Ubiquitination of Cyclin D1 by the SCFFBX4-αB 
Crystallin Complex. Mol. Cell, 24, 355–366. 
69. Kamradt,M.C., Lu,M., Werner,M.E., Kwan,T., Chen,F., Strohecker,A., Oshita,S., Wilkinson,J.C., Yu,C., 
Oliver,P.G., et al. (2005) The small heat shock protein aB-crystallin is a novel inhibitor of TRAIL-induced 
apoptosis that suppresses the activation of caspase-3. J. Biol. Chem., 280, 11059–66. 
70. Mao,Y.-W., Liu,J.-P., Xiang,H. and Li,D.W.-C. (2004) Human alphaA- and alphaB-crystallins bind to Bax 
and Bcl-X(S) to sequester their translocation during staurosporine-induced apoptosis. Cell Death Differ., 
11, 512–526. 
71. Kamradt,M.C., Chen,F., Sam,S. and Cryns,V.L. (2002) The small heat shock protein aB-crystallin negatively 
regulates apoptosis during myogenic differentiation by inhibiting caspase-3 activation. J. Biol. Chem., 277, 
38731–38736. 
72. Kamradt,M.C., Chen,F. and Cryns,V.L. (2001) The Small Heat Shock Protein aB-Crystallin Negatively 
Regulates Cytochrome c- and Caspase-8-dependent Activation of Caspase-3 by Inhibiting Its 
Autoproteolytic Maturation. J. Biol. Chem., 276, 16059–16063. 
73. Ghosh,J.G., Shenoy,A.K. and Clark,J.I. (2007) Interactions between important regulatory proteins and 
human alphaB crystallin. Biochemistry, 46, 6308–6317. 
74. Ghosh,J.G., Houck,S.A. and Clark,J.I. (2007) Interactive Domains in the Molecular Chaperone Human  aB 
Crystallin Modulate Microtubule Assembly and Disassembly. PLoS One, 2. 
75. DiFiglia,M., Sapp,E., Chase,K.O., Davies,S.W., Bates,G.P., Vonsattel,J.P. and Aronin,N. (1997) 
Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science, 
277, 1990–1993. 
76. Arrasate,M., Mitra,S., Schweitzer,E.S., Segal,M.R. and Finkbeiner,S. (2004) Inclusion body formation 
reduces levels of mutant huntingtin and the risk of neuronal death. Nature, 431, 805–10. 
77. Takahashi,T. and Mihara,H. (2008) Peptide and protein mimetics inhibiting amyloid  ??-peptide aggregation. 
Acc. Chem. Res., 41, 1309–1318. 
78. Quraishe,S., Asuni, a, Boelens,W.C., O’Connor,V. and Wyttenbach, a (2008) Expression of the small heat 
shock protein family in the mouse CNS: differential anatomical and biochemical compartmentalization. 
Neuroscience, 153, 483–91. 
79. Quraishe,S. (2010) The sHsp expression signature in the brain and modulation in models of chronic 
neurodegeneration. 
80. Lanneau,D., de Thonel,A., Maurel,S., Didelot,C. and Garrido,C. (2007) Apoptosis versus cell differentiation: 
role of heat shock proteins HSP90, HSP70 and HSP27. Prion, 1, 53–60. 
81. Kore,R. a. and Abraham,E.C. (2014) Inflammatory cytokines, interleukin-1 beta and tumor necrosis factor-
alpha, upregulated in glioblastoma multiforme, raise the levels of CRYAB in exosomes secreted by U373 
glioma cells. Biochem. Biophys. Res. Commun., 453, 326–331. 
82. Frühbeis,C., Fröhlich,D. and Krämer-Albers,E.M. (2012) Emerging roles of exosomes in neuron-glia 
communication. Front. Physiol., 3 APR, 1–7. 
83. Sreekumar,P.G., Kannan,R., Kitamura,M., Spee,C., Barron,E., Ryan,S.J. and Hinton,D.R. (2010) αB 
crystallin is apically secreted within exosomes by polarized human retinal pigment epithelium and 
provides neuroprotection to adjacent cells. PLoS One, 5. 
	  	   74	  
84. Chan,C.S. and Surmeier,D.J. (2014) Astrocytes go awry in Huntington’s disease. Nat. Neurosci., 17, 641–2. 
85. Zhang,Y. and Barres,B. a. (2010) Astrocyte heterogeneity: An underappreciated topic in neurobiology. Curr. 
Opin. Neurobiol., 20, 588–594. 
86. Lobsiger,C.S. and Cleveland,D.W. (2007) Glial cells as intrinsic components of non-cell-autonomous 
neurodegenerative disease. Nat. Neurosci., 10, 1355–1360. 
 
 ____________________________________________________________________________________ 
 
 
3.6. Supplemental Data 
 
 
Supplementary Figure S1 – BACHD mice brains do not present microgliosis and astrogliosis.  
Representative staining of microglia Iba1-positive cells and GFAP-positive cells in WT (n=5), Cryab 
Tg (n=5), BACHD (n=8), DTg (n=7).  
Representative light micrographs of Iba1 (top panel) and of GFAP (bottom panel) immunostaining. 
Despite some minimal astrogliosis found in the BACHD and DTg groups, no obvious and significant 
differences in inflammation - microgliosis (Iba1) or astrogliosis (GFAP) – were found between the 4 
different mice groups.  
Each field is 600 x 600 µm, and the scale bar represents 20 µm. 
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For striatal and cortical counts: 
MatLab Script for Image Analyses 
 
Supplementary Figure S2. Example of the files obtained from our cell counting analyses using a 
Matlab script. On the left panel, we have the result for number of cells outlined in green. In the right 
panel of the figure we are showing the individual cells that were extracted. Different colors show 
different cells. The color feature helps reviewing and manual curating the final counts of cells. (e.g, 
removing noise from the image). 
 
 
Supplemental Tables 
 
Table S1. Cohen's d and effect-size correlation, rYl for Figure 4 - αBc overexpression decreases 
soluble levels of mHtt in BACHD mice. 
Values (mean ± SD): WT (0.02 ± 0.009), Cryab Tg (0.03 ± 0.01), BACHD (1.2 ± 0.04), DTg (0.89 ± 
0.12). 
Groups Cohen’s d Effect size r 
WT vs Cryab Tg -1.53 -0.60 
WT vs BACHD -38.29 -0.99 
WT vs DTg -8.98 -0.97 
Cryab Tg vs BACHD -37.14 -0.99 
Cryab Tg vs DTg -8.79 -0.98 
BACHD vs DTg 3.02 -0.83 
 
 
Table S2. Cohen's d and effect-size correlation, rYl for Figure 4 - αBc overexpression reduces the size 
of S830 inclusion bodies in BACHD mice.  
Values (mean ± SD): BACHD (236.3 ± 53.52), DTg (79.71 ± 16.51) 
Groups Cohen’s d Effect size r 
BACHD vs DTg 3.95 0.89 
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Table S3. Cohen's d and effect-size correlation, rYl for Figure 4 - αBc overexpression rescues the 
number of DARPP-32+ cells in the striatum of the DTg mice.  
Values (mean ± SD): WT (48.14 ± 6.26), Cryab Tg (46.19 ± 6.81), BACHD (42.10 ± 10.76), DTg 
(47.27 ± 7.21) 
Groups Cohen’s d Effect size r 
WT vs Cryab Tg 0.29 0.15 
WT vs BACHD 0.69 0.32 
WT vs DTg 0.13 0.06 
Cryab Tg vs BACHD 0.45 0.22 
Cryab Tg vs DTg -0.15 -0.08 
BACHD vs DTg -0.56 -0.27 
 
 
Table S4. Cohen's d and effect-size correlation, rYl for Figure 4 - αBc over-expression rescues the 
number of NeuN+ cells in the cortex of the DTg mice.  
Values (mean ± SD): WT (93.27 ± 9.27), Cryab Tg (90.52 ± 9.91), BACHD (75.79 ± 13.24), DTg 
(89.71 ± 8.48) 
Groups Cohen’s d Effect size r 
WT vs Cryab Tg 0.28 0.13 
WT vs BACHD 1.37 0.56 
WT vs DTg 0.39 0.19 
Cryab Tg vs BACHD 1.15 0.49 
Cryab Tg vs DTg 0.09 0.04 
BACHD vs DTg -1.13 -0.49 
 
 
Table S5. Cohen's d and effect-size correlation, rYl for Figure 4 - αBc over-expression rescues the 
number of NeuN+ cells in the striatum of the DTg mice.  
Values (mean ± SD): WT (69.74 ± 6.74), Cryab Tg (70.32 ± 6.72), BACHD (61.82 ± 12.7), DTg 
(69.84 ± 11.41) 
Groups Cohen’s d Effect size r 
WT vs Cryab Tg -0.09 -0.04 
WT vs BACHD 0.78 0.36 
WT vs DTg -0.01 -0.01 
Cryab Tg vs BACHD 0.84 0.39 
Cryab Tg vs DTg 0.05 0.02 
BACHD vs DTg -0.65 -0.31 
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Chapter 4. 
Cell non-autonomous potential 
antioxidant effects of αB-crystallin in 
HD  
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4.1. Introduction 
 
The mechanism by which mHtt causes neuronal dysfunction and degeneration in 
HD is still not fully understood. Nevertheless, among other essential cellular pathways 
such as apoptosis, oxidative stress, inflammation, mitochondrial and metabolic 
dysfunction, have been shown to play important roles in the pathogenesis of HD (1, 2). 
Oxidative stress is one of several dysfunctional mechanisms described in HD (3) 
(1), which may result from impaired mitochondrial function, due to interactions with mHtt 
(4) and imbalanced redox homeostasis. Altered oxidative stress have been observed in 
both central and peripheral samples of HD patients (5) and in some animal models of the 
disease (6). In addition, a study in primary cell culture models from BACHD mice showed 
that mHtt does not directly affect metabolic activity in a cell autonomous manner (7). In 
fact, co-culture of neurons with astrocytes from WT or BACHD mice identified mutant 
astrocytes as a source of adverse non-cell autonomous effects on neuron energy 
metabolism possibly by increasing oxidative stress. These results suggest that astrocyte-to-
neuron signaling is involved in early metabolic alterations in HD (7). These data are in 
agreement with our findings in Chapter 3 that show the protective effect of astrocytic 
overexpression of αBc in the BACHD mouse model may occur through a cell non-
autonomous manner (8). 
αBc is a pleiotropic protein, and in addition to chaperone activity, αBc performs 
multiple other functions: prevents oxidative stress-induced cell death (9–12), protects from 
GFAP toxicity and glutamate excitotoxicity (13), inhibits inflammation (14–17), prevents 
disruption of cytoskeletal assembly (18), protects against hydrogen peroxide (H2O2) 
damage (19) by inhibiting caspase-3 activation. 
Here, we explored the cytoprotective role of αBc against various stresses such as 
oxidative stress and modulation of cell death and mHtt-induced downstream pathways in 
the BACHD mouse model. 
To better understand whether astrocytic αBc overexpression and astrocyte–neuron 
interactions modulate neuropathological deficits in BACHD, we used caspase-3 
expression and activity as an apoptotic marker, measured carbonyl content as a 
measurement for oxidative stress, and other HD pathological markers, in brain tissue from 
our mice cohort as well as primary neurons and astrocytes cultures from the same cohort. 
Our results suggest that BACHD do not exhibit strong phenotypes of caspase-3 activation 
or increased levels of carbonylated proteins. However, we observed a protective trend of 
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astrocytic αBc in BACHD mice. Our data suggests that αBc antioxidant properties may 
play a role in our BACHD model in a cell non-autonomous manner. 
 
4.2. Materials and Methods 
 
Cell culture 
Primary astrocytes 
Highly purified astrocytes cultures were prepared from 1- or 2-day-old pups from 
WT, Cryab Tg, BACHD and DTg mice of either sex as previously described (20). Briefly, 
forebrains were removed aseptically from the skulls, the meninges were carefully excised 
under a dissecting microscope and the neocortex was dissected free of brainstem, 
thalamus, striatum, and hippocampus. The cells were dissociated by passage through 
needles of decreasing gauge size three times with a 5-ml syringe. The cells were seeded on 
six-well plates in Dulbecco's Modified Eagle's medium (DMEM Life Technologies) 
containing 5.5  mM glucose and supplemented with 10% fetal bovine serum, 2  mM L-
glutamine (Gibco, Life Technologies) and antibiotics (Penicillin-Streptomycin, Gibco, 
Life Technologies) in a final volume of 2  ml/well and incubated at 37  °C in an atmosphere 
containing 5% CO2/95% air. The culture medium was renewed 3 to 4 days after seeding 
and subsequently three times per week. Cultures were used between 19 to 21 DIV. 
Neuron–Astrocyte Cell-Insert Coculture 
Astrocyte cultures were prepared as described above. After 10 days in vitro, and 1 
week before neuronal culture preparation, astrocytes were treated with trypsin and seeded 
on cell culture inserts (35-3102, Falcon) with 1 mm pores. Primary culture of cortical 
neurons was made from embryonic days 18-19 (E18-19) mouse embryos. Timed pregnant 
females from our BACHD and Cryab Tg cohort mice were sacrified with isoflurane and 
embryos quickly removed and dissected on cooled Hank’s balanced sodium salts without 
Ca2+ and Mg2+. Cortices were isolated and incubated for 15min at 37ºC in 0.3mg/ml 
DNase I (Sigma-Aldrich). Tissues were mechanically dissociated with P1000 and P200 
pipettes. Cells were finally concentrated by centrifugation (20ºC, 10minutes, 1,000g) and 
resuspended in serum-free Neurobasal medium supplemented with 2% B27 supplement 
(Invitrogen, Carlsbad, CA, USA), 1% antibiotic–antifungal mixture (Invitrogen) and 
0.5mM L-glutamine (Sigma-Aldrich). Cells were plated at a density of 2x105 cells/cm2 in 
12- or 24-well plates coated with 50mg/ml of poly-D-lysine (Sigma Aldrich). Astrocytes 
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inserts were placed onto neurons 2 days after neurons seeding. Cultures were used for 
experiment 13 days after neuron seeding.  
 
Genotyping 
Mouse-tail DNA was analyzed by PCR to determine the genotypes. The BACHD 
transgene was identified as described in the section 3.2 Material and Methods, Chapter 3.  
The Cryab transgene was identified as described (21).  
 
Quantitative real-time PCR (QPCR) 
Mice were anesthetized with Avertin (tribromoethanol, 250 mg per kg) and 
perfused transcardially with 0.9% saline, and brains were removed. RNA was harvested 
from frozen mice striatum and cortex (striatum was microdissected as described (22) with 
an RNeasy Mini kit (Qiagen, USA), according to the manufacturer's instructions. RNA 
was immediately reverse transcribed to cDNA with Multiscribe™ reverse transcriptase 
(Applied Biosystems, USA) and stored at −20°C. For HD associated gene expression 
studies and quantification of caspase-3 mRNA, quantitative real-time PCR (QPCR) was 
performed using FAST SYBR Green Mastermix (Applied Biosystems, USA) as provided 
by the manufacturer and thermal cycling was performed using an ABI Prism 7900 HT 
Sequence Detector (Applied Biosystems, USA) with the following program: UNG 
activation (50 °C for 2 min), initial denaturation (95 °C for 10 min), and then 40 cycles of 
denaturation (95 °C for 15 seconds) then annealing and extension (60 °C for 1 min), 
followed by a disassociation stage for melting curve analysis. Analysis of fluorescence 
data from genes of interest and from the control gene ATP synthase subunit 5b (Atp5b) 
(23), was performed using the online analysis tool QPCR (24). Amplification efficiency 
was calculated for each primer pair using serially diluted standards. This efficiency was 
used to convert threshold cycle (number of PCR cycles required to reach an arbitrary 
threshold fluorescence value) into relative gene expression using the efficiency corrected 
delta Ct method as described (25). For each sample, expression of the gene of interest was 
normalized to the control gene Atp5b. All data are expressed as a fold change compared to 
WT mice, and all primers are listed in Table 1. Primers were designed using the online 
Roche Universal Probe Library Assay Design Center (Roche Applied Science, USA) or 
the online tool Primer-BLAST (NCBI). Primer specificity was evaluated using Primer-
BLAST (NCBI) and melting curve analysis. 
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Protein extraction 
Mice were anesthetized with Avertin (tribromoethanol, 250 mg per kg) and 
perfused transcardially with 0.9% saline. Brains were removed, micro-dissected in ice-
cold PBS and immediately. Frozen mice striatum and cortex were homogenized in ice-
cold standard RIPA buffer (150 mM NaCl, 1% NP-40, 0.1% sodium dodecyl sulfate, 0.5% 
sodium deoxycholate, 50 mM Tris, pH 7.4) supplemented with complete protease 
inhibitors (Roche Applied Science) and spun at 14,000 × g for 30 min at 4 °C. 
 
Western blotting  
Proteins (10–20 µg/well) from brain tissue and primary cultures were separated on 
a 4–12% NuPAGE Bis-Tris gel (Life Technologies) and transferred onto nitrocellulose 
membranes, which were incubated for 1 h in 5% bovine serum albumin (Sigma-Aldrich) 
diluted in Tris-buffered saline containing 0.05% Tween (BSA-TBST). Immunoblots were 
probed and incubated overnight at 4 °C in rabbit anti-αB-crystallin (1:1,000, Stressgen), or 
anti-B-tubulin (Abcam, ab6046, 1:20,000) antibodies diluted in BSA-TBST. Appropriate 
IRDye secondary antibodies (LI-COR Biosci) were used at a 1:20,000 dilution. Images 
were captured with the Odyssey CLx (LI-COR Biosci). 
Caspase-3 activity assay  
Caspase-3 activity was determined by colorimetric assay (R&D Systems, 
Minneapolis, MN), according to the manufacturer’s instructions. In brief, we tested brain 
tissue (striatum and cortex) as well primary neurons and astrocytes. As we did not 
observed caspase-3 upregulation in BACHD mice, we later induced apoptosis by adding 
300 mM H2O2 to primary cultures for 1 h. Cells were then harvested and aliquots of 2.5x 
106 cells were used for caspase-3 activity assays. Cell lysates were incubated in the 
presence or absence of 50 ml DEVD-pNA for 1 h at 37ºC, and absorbance was measured 
at 405 nm using a micro-plate reader. Not induced and induced cells without substrate 
served as background controls. In addition, induced cells were incubated with DEVD-
DHO, an inhibitor of caspase-3, to correlate protease activity and signal detection. 
 
Protein carbonyl content assay 
We measured protein carbonyl groups as biomarkers of oxidative stress (26). 
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Protein carbonyls were measured from tissue and primary cell homogenates using 2,4-
dinitrophenylhydrazine (DNPH) derivatization, according to the manufacturer's directions 
(Protein Carbonyl Assay Kit, cat#ab126287; Abcam).  
Briefly, we tested brain tissue (striatum and cortex) as well primary neurons and 
astrocytes. 100 µl of sample containing approximately 0.5-2 mg protein per assay, 
including a reagent background control by using 100 µl of dH2O alone were added to 100 
µl and incubated for 10 min. TCA and acetone were added for washing steps to remove 
the nucleic acids that could interfere in the reaction. After the washing steps, 200 µl of 
Guaninine solution was added and samples were sonicated briefly and protein was re-
solubilized easily. After a very brief spin, 100 µl of each sample was transferred to a 96-
well plate. OD was measured at 375 nm in a micro-plate reader. 
 
4.3. Results 
 
4.3.1. BACHD mice do not induce upregulation of Caspase-3 and BACHD 
astrocytes overexpressing αBc are more resistant to H2O2-induced toxicity 
 
In vitro cell studies showed that αBc confers protection against apoptosis through 
the regulation of caspase-3, a proapoptotic factor (19). In addition, αBc was also shown to 
sequester the p53 tumor suppressor, thus preventing apoptosis (27). 
Caspase-3 expression is upregulated in brains of a mouse model of HD, R6/2 mice 
(28), and a recent study has also reported the same effect in hearts of aged BACHD (29). 
Thus, caspase-3 upregulation may play a role in HD progression. We next wanted to 
determine whether BACHD mice brain displayed increase of caspase-3 levels, and if αBc 
over-expression could have a protective effect in our DTg mouse brains when compared to 
BACHD.  
Reverse transcriptase–quantitative polymerase chain (RT-qPCR) reaction was 
performed on cortical and striatal samples from brain lysates of the Cryab Tg crossed with 
BACHD that we studied in Chapter 3.  
Surprisingly, the levels of caspase-3 were not significantly upregulated in both 
cortex and striatum of BACHD brain lysates when compared to the control littermates WT 
(Fig. 1A).  This suggests that aged brains of BACHD mice do not present transcriptional 
upregulation of caspase-3 in the most sensitive brain regions of HD. We have also 
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analyzed the protein levels, but did not find cleaved caspase-3 in blots of brain lysates 
from our mice cohort (data not shown).  
To rule out that there could be differences in caspase-3 activity, we then measured 
caspase-3 activity using a common colorimetric assay. We have used brain lysates from 
striatum and cortex, as well as primary astrocytes and neurons from our mice cohort, to 
determine if the stage of the disease (primary cells vs aged brains) could be having a role 
on caspase-3 expression and/or activity (Fig. 1B,C). Our results showed no caspase-3 
activity induction in both striatum and cortex of BACHD aged brains (Fig 1B), and in 
primary neurons and astrocytes (Fig. 1C) from the mice cohort. These results suggest that 
full-length mHtt in aged BACHD and also in primary cultures (neurons and astrocytes) 
does not directly or indirectly modify levels and activity of caspase-3. 
Oxidative stress is mediated by increases in reactive oxygen species (ROS) 
including superoxide (O2−), hydrogen peroxide (H2O2), hydroxyl radical (OH−), and 
reactive nitrogen species such as peroxynitrite (ONOO−). We then decided to directly 
insult the primary cultures of neurons and astrocytes with H2O2 to induce oxidative stress 
in these cells as shown previously (19), and determine if αBc could exert a protective 
effect against H2O2 – induced toxicity, as previously observed in studies in cell lines (9, 
19). We next wanted to demonstrate that our Cryab Tg and DTg primary astrocytes were 
over-expressing αBc. We observed a 6-7 fold upregulation of αBc in both Cryab Tg and 
DTg when compared to WT and BACHD (Fig1 D,E). In contrast, neuronal population of 
both αBc transgenics did not show upregulation of αBc (data not shown) supporting that 
any protective effect of αBc, driven by a GFAP promoter, is a cell non-autonomous effect. 
After inducing primary neurons and astrocytes with 300 uM of H2O2, caspase-3 activity 
increased in both cell types. Primary neurons and astrocytes are sensitive to the toxicity 
induced by H2O2 resulting in caspase-3 activity upregulation ∼5 fold for neurons and ∼4 in 
astrocytes, when compared to no treatment conditions for each genotype (Fig.1F). Despite 
responding to the toxic stimulus caused by H2O2, the different genotypes, expression of 
mHtt and/or αBc, in primary neurons did not play a role in this response. In contrast, in 
astrocytes, the αBc transgenics were more resistant to the toxic effect of H2O2 treatment 
and showed a significant decrease on caspase-3 activity when compared to WT and 
BACHD, respectively (Fig. 1F). DTg astrocytes showed a partial rescue against H2O2 
damage suggesting endogenous mHtt expression in DTg astrocytes decreased their 
antioxidant effect when compared to Cryab Tg. These results support the potential 
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antioxidant role of astrocytic αBc against H2O2 – induced toxicity as previously reported 
(19). 
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Figure 1. BACHD mice do not have upregulation of caspase-3 and BACHD astrocytes over-
expressing αBc are more resistant to H2O2 induced toxicity.  
Caspase-3 expression was evaluated by QPCR (A) and caspase-3 activities using a colometric 
assay (B,C and F) in  striatum and cortex of 13 month-old brains of WT, Cryab Tg, BACHD and 
DTg (n=6 per genotype), as well as neurons and astrocytes primary cultures of these mice (n=5 
embryos/pups). (A) Caspase-3 mRNA is not upregulated in BACHD mice. Caspase-3 mRNA 
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expression was not statistically significant different among the different genotypes (when 
normalized to WT). (B) Caspase-3 activity was also not induced in striatum and cortex of any 
group of our mice cohort. (C) Despite a trend for an increase of caspase-3 activity in BACHD 
astrocytes, no statistical difference was observed in both neurons and astrocytes from WT, Cryab 
Tg, BACHD and DTg (when normalized to WT). Caspase-3 activity was not different among the 
different genotypes. (C, D) Western Blot and quantification of showing 6/7 fold over-expression in 
αBc protein levels in astrocytes of Cryab Tg and DTg, which is expression is driven by a GFAP 
promoter. (F) Since expression of mHtt on BACHD was not enough induce caspase-3 activity, 
oxidative stress was induced on primary neurons and astrocytes by H2O2, treatment mHtt. Both 
primary neurons and astrocytes were sensitive to the toxic insult, but astrocytes were significantly 
more resistant to stress than neurons. αBc over –expression transgenics (Cryab Tg and DTg) 
exhibited an antioxidant and protective effect when compared to WT and BACHD. DTg astrocytes 
were more resistant than BACHD astrocytes when exposed to H2O2, treatment. 
Data represent Means±SD. Two –way nova analysis were performed followed by multiple 
comparison by Tukey post-hoc tests. Statistical significance was achieved when p< 0.05. 
 
4.3.2. BACHD astrocytes affect neuronal carbonyl content by a non-cell 
autonomous mechanism  
 
Oxidative stress and damage occurs in cells, animal models and tissues from HD 
patients (2, 5, 6). Carbonyl groups are initiated into proteins by oxidative reactions of 
nitrogen oxides or by metal-catalysed oxidation in the tissue. These are an important and 
immediate biomarker of oxidative stress (30, 31). The DNP hydrazones (DNPH) tagging 
of protein carbonyls has been a common measure of oxidative stress (30). A recent study 
reported that BACHD astrocytes increased the expression of carbonyl residues in both WT 
and BACHD neurons. These results suggest that mutant astrocytes may be the  source of 
adverse non-cell autonomous effects on neuron dysfunction and death (7). To further 
investigate the potential of αBc to modulate oxidative stress in vivo, we used a protein 
carbonyl content assay. We wanted to determine first, whether protein carbonylation 
levels were altered in BACHD brains when compared with WT at 13 months; and second, 
whether this could be attenuated by astrocytic αBc over-expression (Fig. 2A). Presence of 
carbonyl groups, marker for oxidative stress (26), was measured in the 13 months brain 
regions, striatum and cortex, of WT,Cryab Tg, BACHD and DTg. Expression of mHtt in 
both striatum and cortex of BACHD and DTg mice failed to induce upregulation of 
carbonyl protein content. (Fig. 2A). We then performed the same experiment on primary 
neurons and astrocytes from our mice cohort (Fig 2B). Despite a trend for an increase of 
carbonyl content, especially in BACHD astrocytes, we did not detect statistically 
significant difference on both neurons and astrocytes from WT, Cryab Tg, BACHD and 
DTg (when normalized to WT). Interestingly, a recent study (7) using neuron-astrocyte 
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co-culture system has reported that BACHD astrocytes are the source of oxidative stress 
(ROS and carbonyl groups formation) in both WT and BACHD neurons. This study 
suggested a cell non-autonomous adverse effect from mHtt expressed astrocytes in 
neuronal populations that are more prone to cell death (7, 32).  
 
 
Figure 2. BACHD astrocytes affect neuronal carbonyl content by a non-cell autonomous 
mechanism. (A) BACHD brains do not induce upregulation of carbonyl protein content. Presence 
of carbonyl groups, marker for oxidative stress, was measured in the 13 mo brain regions, striatum 
and cortex, of WT,Cryab Tg, BACHD and DTg (n=6 per genotype). Carbonyl expression was not 
statistically significant different among the different genotypes. (when normalized to WT). (B) 
Same assay was then measured in neuronal and astrocytic primary cultures obtained from same 
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mice cohort (n=5 different embryos/pups). Despite a trend for an increase of carbonyl content in 
BACHD astrocytes, no statistical significant difference was observed in both neurons and 
astrocytes from WT, Cryab Tg, BACHD and DTg (when normalized to WT). Carbonyl expression 
was not different among the different genotypes. (C) Diagram for Co-Culture experiments. (D) 
BACHD and DTg astrocytes affected neuronal carbonyl content by a non-cell autonomous 
mechanism. αBc overexpression did not confer a protective effect against carbonyl groups 
formation and hence oxidative damage was present in neuronal population exposed to both 
BACHD and DTg astrocytes. Data represent Means±SD. Two –way nova analysis were performed 
followed by multiple comparison by Tukey post-hoc tests. Statistical significance was achieved 
when p< 0.05. 
 
We decided to test this system (Fig. 2C) in our model, to evaluate whether BACHD 
astrocytes could induce neuronal toxicity through carbonyl formation, and whether αBc 
astrocytic over-expression could rescue the toxic effects (Fig 2D). As observed before, 
BACHD astrocytes were able to significantly affect neuronal carbonyl content in WT, 
Cryab, BACHD and DTg populations, by a non-cell autonomous mechanism. However, 
αBc overexpression did not confer protective effect against carbonyl groups formation and 
therefore oxidative stress induced by carbonyl content expression was present in all 
neuronal populations exposed to both BACHD and DTg astrocytes  (Fig. 2D). 
 
4.3.3. The levels of HD pathology-related markers is not altered in the brains 
of BACHD mice  
 
To gain a broader understanding of the neuropathological status, as well as 
transcriptional dysregulation present in HD (33–35), we used QPCR and western-blot to 
quantify mRNA and protein levels, respectively, of HD related genes in cortex and 
striatum from 13 month old WT, Cryab Tg, BACHD and DTg mice. We chose genes 
shown to be involved in diverse pathomechanisms in HD, and that have shown to be 
modulated by αBc or other sHsps, that share identical properties to αBc. 
We observed few significant differences in gene expression in BACHD mice 
(Table 2). Of note that brain derived neurotrophic factor (BDNF) downregulation is a 
robust feature on human HD brain samples (34, 36) and in multiple mouse models of HD 
(37–39) , was not significantly downregulated in BACHD mice. Generally, the large-scale 
upregulation or down-regulation of HD-related genes that is observed in human HD brains 
is not paralleled in late-stage BACHD brains.   
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Table 1. HD-related genes tested in αBc overexpressing animals.   
Function/Markers QPCR WB αBc OE effect 
Chaperones 
(HSR) 
   
Hsp70 
Hsp40 
Hsp27 
n.s 
n.s 
n.s 
n.s 
n.s 
n.s 
 
Apoptosis / 
Oxidative stress 
   
p53 
Caspase-3 
 
iNOS 
n.s 
a trend 
in BACHD 
n.s 
n.s 
n.s 
 
n.s 
 
Protective effect 
against H2O2 
Excitotoxicity    
Glut1 (EEAT2) n.s   
Neurotrophic factor    
BDNF n.s Not detected  
Neurotransmitters 
Receptors 
   
DR1, DR2 n.s   
Autophagy    
LC3 n.s n.s  
Inflammation    
IL-1B; IL-2; IL-6; IL-12 n.s -  
HSR – Heat Shock Response 
 
4.4. Discussion 
 
Damage to a specific set of key partner cells as well as to vulnerable neurons may 
account for the selective susceptibility of neuronal subtypes in many human 
neurodegenerative diseases, including Huntington’s disease (HD), Parkinson’s disease 
(PD), prion disease, the spinal cerebellar ataxias (SCAs), and Alzheimer’s disease (AD). 
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We recently showed that overexpression of the sHsps αBc was shown to suppress mHtt-
mediated neurotoxicity and behavioral abnormalities in the BACHD mouse model of HD 
(8). Expression of αBc was driven through a GFAP promoter, therefore overexpression of 
this sHsp was targeted in astrocytes (13). Besides neurons, growing evidence 
demonstrated that the expression of mHtt in glial cells, namely in astrocytes can contribute 
to the pathogenesis of HD (32, 40). Therefore we decided to investigate at a deeper level 
the cell non-autonomous effect of αBc over-expression in the BACHD mice observed in 
Chapter 3. 
Our data suggests that BACHD astrocytes may be the source of adverse cell non-
autonomous effects on neuronal toxicity caused by mHtt aggregation, oxidative stress, and 
cellular dysfunction. Astrocytic αBc may alleviate neuronal death by not only preventing 
mHtt misfolding and downstream toxic events as a chaperone, but presenting an 
antioxidant role and alleviating neurons from oxidative stress, apoptosis cascades and 
excitotoxicity events.  
We hypothesize that astrocytic αBc has an important modulatory role during HD 
since the ability to effectively initiate the heat shock response (HSR), and other 
homeostatic cellular pathways (e.g., apoptosis, oxidative stress) in which αBc functions, 
are compromised during HD disease progression (41). We should also take into account, 
as a chaperone with multi-functional capabilities, αBc may alleviate stress by promoting 
ubiquitin/proteasomal degradation of corrupt proteins (42, 43) preventing apoptosis (9, 11, 
12, 44) or by stabilizing intermediate filaments and the cytoskeleton integrity (45, 46). 
As the presence of mHtt in BACHD did not compromise the transcription of the 
major genes and protein levels known to be involved in the HD pathobiology, we 
investigated other mechanisms that could be involved. 
The most obvious candidate mechanism for chaperone-mediated rescue of HD 
neurotoxicity is inhibiting or reversing Htt aggregate (fibrils/polymers) formation. 
Although mHtt is expressed in glial cells, the neuronal population contains most of mHtt 
aggregates (47, 48). Our results from Chapter 3 indicate that αBc modulates mHtt levels 
and the features of IBs in a typical chaperone manner. Overexpression of chaperones may 
reduce large IBs by preventing oligomer formation, and oligomeric precursors may be the 
most toxic species (49–51). As with most Hsps, sHps can also be important for protein 
stability and protein turnover. Evidence suggests that affinity of αBc for its chaperone 
substrates is modulated by its chaperone oligomerization status and the functional 
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structure of αBc is a dimer, which results from interactions of β-strands in the α-crystallin 
domain (52, 53).  
Another hypothesis also suggests that BACHD astrocytes may fail to provide 
adequate metabolic support to neurons, in particular lactate. Lactate, released by 
astrocytes, has been shown to sustain glutamatergic neurotransmission and synaptic 
plasticity (54, 55). Although we did not measure extracellular lactate and the expression of 
the monocarboxylate transporters responsible for lactate fluxes across cells in our model, 
this hypothesis deserves further examination particularly in the context of increased 
oxidative stress. 
Other possibility is related to chronic inflammation, which involves glia and is 
known to accelerate disease progression in HD. Indeed, αBc is critical for DRD2-mediated 
modulation of innate immune response in astrocytes (56) . This study has shown that 
astrocytic DRD2 activation normally suppresses neuro-inflammation in the central 
nervous system through a αBc -dependent mechanism, and provides a new strategy for 
targeting the astrocyte- mediated innate immune. Although we did not directly test this 
hypothesis, we performed QPCR for a variety of cytokines (Table 1) and immunostaining 
of microglia using Iba-1 antibody and the astrocytic GFAP in the brain of 13-month old 
BACHD and did not find any cytokine transcriptional dysregulation and activated 
microglia or activated astrocytes (surrogate markers of neuroinflammation – microgliosis 
and astrogliosis (Chapter 3, sup Fig1.), indicating no significant inflammation in these 
mice. In addition, we suggest that BACHD astrocytes have a reduced antioxidant potential 
leading to an increased oxidative stress in neurons. We indeed provided evidence that 
oxidative stress is increased in BACHD mice and is induced in vitro in neurons when co-
cultured with BACHD astrocytes. However, astrocytic αBc overexpression is suggested to 
confer antioxidant protection, especially against H2O2 insults, consistent with previous 
studies that described the anti-apoptotic effect of αBc mediated via the disruption of the 
proteolytic activation of caspase-3 (11). By directly binding to procaspase-3, αBc inhibits 
the pro-apoptotic proteins, bcl-X(S), Bax and p53 by preventing their translocations from 
cytosol into mitochondria during apoptosis (12, 27). However, we failed to detect these 
effects in p53 and caspase-3 expression and activity in our BACHD mouse model system 
(Table 1). We observed few significant differences in gene expression in BACHD mice 
(Table 1). Of note that brain derived neurotrophic factor (BDNF) downregulation is a 
robust feature on human HD brain samples (34, 36) and in multiple mouse models of HD 
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(37–39) , was not significantly downregulated in BACHD mice. Generally, the large-scale 
upregulation of HD-related genes that is observed in human HD brains is not paralleled in 
late-stage BACHD brains. However, our data do not establish a mechanism by which 
overexpression of αBc in astrocytes is likely to play a critical function in the modulation 
of mHtt and oxidative stress in the context of BACHD mice. These findings open up new 
avenues in the investigation of Hsps and sHsps overexpression in astrocytes and their 
potential protective role in neurons through a cell non-autonomous manner in HD and 
other proteinopathies. 
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Chapter 5. 
_____________________________________ 
Genetic deficiency of αB-crystallin does 
not aggravate the disease progression of 
the BACHD mouse model of HD  
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5.1. Introduction 
 
Accumulation of misfolded and aggregated proteins is a pathological hallmark of 
several neurological disorders (1). Members of the sHsp family, whose expression is 
regulated by the heat shock transcription factor 1 (HSF1), are known to constitute a line of 
defense to protect cells from the deleterious effects caused by toxicity associated with 
misfolded proteins (2). In addition, sHsps are pleiotropic proteins, i.e., they can protect cells 
from a variety of environmental conditions such as oxidative stress, heat, apoptosis, 
inflammation and by other degradation mechanisms (2, 3). Therefore, their importance in 
proteinopathies should be further understood. sHsps share a conserved α-crystallin domain of 
80–100 amino acids at their C-terminus whereas their N-terminal regions are highly variable 
in sequence and length (4). The sHsps form dynamic oligomeric structures ranging from 9–50 
subunits associating as either homo- or hetero-multimeric complexes (5). It has been proposed 
that the ATP-independent sHsps help in refolding of denatured proteins by holding them in a 
reactivation-competent state and target them to subsequent refolding or degradation with the 
help of ATP-dependent chaperones like Hsp70 and Hsp40 (6, 7). The human and mouse 
genomes contain for 10 genes for sHsps differing between 45 and 85% in sequence (8, 9). 
Point mutations in human sHsps lead to several aggregation diseases (4) – for example, 
mutations in αA-crystallin leads to cataract (10), mutations in αBc leads to desmin-related 
myopathy (11–14), missense mutations in HSP27 is associated with Charcot-Marie-Tooth 
disease (15, 16). Induction of αBc has been noted in Alexander’s disease (17), Creutzfeldt-
Jacob disease (18), Parkinson’s disease and taupathies (19) and in Alzheimer’s disease (11, 
20, 21). In contrast with findings in other protein aggregation diseases of the CNS, elevation 
of αBc and other sHsps have not been observed in the poly-Q diseases (2). Studies in the R6/2 
(22) and BACHD (23) mice models of HD found reduced overall levels of αBc at the end of 
the disease course. 
In addition, expression of a mHtt fragment in mice lacking αBc, markedly accelerated 
the onset and severity of aggregation, demonstrating that the endogenous chaperone activity 
of  αBc suppresses aggregation in vivo. Moreover, studies using a mouse model deficient in 
αBc crossed with an AD transgenic mouse model has shown that lack of αBc increases 
behavioral impairment in AD disease progression (24, 25). Our previous studies (Chapter 3), 
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have shown that elevating αBc could protect from behavioral and neuropathological deficits 
in BACHD mice (23). Thus, we hypothesized that endogenous αBc protects cells against 
mHtt toxicity and play a role in HD disease progression. To note, that targeted deletion of αBc 
also disrupted the adjacent gene, HspB2, due to the proximity of the promoter sequences (26). 
Similar to αBc, HspB2 is expressed in skeletal and cardiac muscles where it is often localized 
to the Z lines and has also been shown to associate with and activate myotonic dystrophy 
protein kinase (20). Importantly HspB2 is not expressed in the brain and is not presently 
known to be involved in protein aggregation prevention (4, 26). Also, mice knocked-out for 
αBc and HspB2 are viable suggesting that it is either non-essential or redundant during 
development. Older knockout mice consistently lost weight and body fat and subsequently 
developed severe spine curvature (kyphosis) and skeletal muscle degeneration (26). 
Therefore, we decided to test for the first time the impact of αBc (and HspB2) deletion in HD 
in the BACHD mice. For this purpose, we crossed αBc/HspB2 deficient (CRYAB-/-HSPB2-/-) 
mice with the BACHD mouse model of HD, previously used in our studies. Transgenic and 
non-transgenic mice in chaperone-sufficient or deficient backgrounds were examined for 
representative behavioral paradigms for motor and cognitive functions: motor and locomotor 
activity was evaluated by rotarod and balance beam, spatial orientation and locomotion was 
monitored by open field test and anxious behavior was evaluated on elevated plus maze. 
Unexpectedly, αBc/HspB2 deficiency did not increase the severity of the BACHD disease 
progression. Instead, αBc/HspB2 modulated the body weight on BACHD mice and this effect 
play a role on the behavioral readouts. Our data suggests and highlights that all chaperones 
have many cellular functions and when chronically overexpressed or deleted, may have 
deleterious as well as beneficial consequences on metabolism and other essential 
physiological functions, causing the protein networks to further adjust to neutralize potentially 
damaging effects. Further studies should pursue unique and single deletions of αBc and other 
sHsps to clarify novel potential roles of these proteins in the context of neurological disorders. 
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5.2. Materials and Methods 
 
Animals and breeding strategy 
Animal experiments were approved by the Institutional Animal Care and Use 
Committee of the University of California, San Francisco. Mice were housed, bred and 
maintained in compliance with National Institutes of Health guidelines. BACHD (BACHD tg) 
mice in C56Bl/6J background were obtained from Dr. William Yang (University of California, 
Los Angeles) and one breeding pair of CRYAB-/-/HSPB2-/- (or αBc/HspB2 deficient) mice in 
C56Bl/6J background (26) were gifted kindly by Dr. John Clark, (University of Washington, 
Seattle) MD. Both lines were maintained by breeding to wild-type (WT) 129Sv animals from 
the Jackson Laboratory (Bar Harbor, ME). To test if deletion αBc/HspB2 could modulate HD 
progression, we crossed the αBc/HspB2 mice to BACHD mice. Progeny from this breeding 
resulted CRYAB+/-/HSPB2+/-, mice with equal numbers of non-transgenic and transgenic. The 
CRYAB+/-/HSPB2+/- transgenic mice were crossed with CRYAB+/-/HSPB2+/- littermates to 
generate (i) CRYAB+/+/HSPB2+/+, BACHD Tg 0/0 (hereafter referred to as WT); (ii) 
CRYAB+/+/HSPB2+/+, BACHD Tg+/0 (hereafter referred to as BACHD); (iii) CRYAB-/-
/HSPB2-/-, BACHD Tg0/0 (hereafter referred to as KO) and (iv) CRYAB-/-/HSPB2-/-, BACHD 
Tg+/0 (hereafter referred to as BACHD-KO) in addition to parental genotypes CRYAB+/-
/HSPB2+/-, BACHD Tg0/0  (hereafter referred to as HET) and CRYAB+/-/HSPB2+/-, BACHD 
Tg+/0, (hereafter referred to as BACHD-HET). All groups of mice were mice and were used 
for behavioral studies and HD-associated biochemical studies.  
 
 
Genotyping 
Genotypes of the mice were confirmed by PCR of tail genomic DNA using 
appropriate primers as described in Brady et al (26) for KO mice genotyping and in Gray et al 
(27). The use of littermates for all genotypes minimizes the effect of out-crossing the mice. 
The genetic variations between the two parental mouse strains are expected to affect all six 
experimental genotypes identically. 
 
Behavioral assays 
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For all behavior experiments, experimenters were blinded to genotype. Experimental 
readouts were analyzed at 3, 7, 10 and 13 months for rotarod and balance beam to evaluate 
HD phenotype progression. All cages contained at least one mouse from each genotype, and 
mice were given environmental enrichment. Mice were subject to a 12-h light/dark cycle. 
Behavioral analysis of WT, HET, KO, BACHD, BACHD-HET and BACHD-KO, were done 
blind to genotype.  
Elevated plus maze, Open Field, Rotarod and Balance Beam were performed as 
previously described (Chapter 3, Materials and Methods Section – Behavioral Assays), for the 
3, 7, 10 and 13 times points.  
 
5.3. Results 
 
5.3.1. Abnormal genotype distribution in BACHD combined with αBc/HspB2 
deficient mice. 
 
We have previously observed (Chapter 3, Fig. 1) that αBc protein levels decreased in a 
time-dependent manner in BACHD brains. Therefore, we hypothetized that the overproduced 
mHtt in BACHD could affect proteostasis not only by increased demand for chaperone 
function but also because of its reduced expression. In this mouse model, we speculated that if 
αBc could protect the mice from mHtt-mediated neuronal dysfunction, then in its absence 
these deficits should manifest at an earlier age. It was demonstrated that the BACHD mice 
showed more robust behavioral around 6 months of age (27). Since the mice deficient for 
αBc/HspB2 showed debilitating phenotypes about 9-10 months of age (26), we decided to 
investigate the behavioral phenotypes of WT (n=20), HET (n=20), KO (n=27)  BACHD 
(n=20), BACHD-HET (n=20), and BACHD-KO (n=12).  
The observed offspring genotypes were compared, and we noticed abnormal genotype 
distribution: the group of BACHD-KO genotype had significantly fewer mice than expected. 
Comparatively with all the other genotypes that had numbers according to the expected 
Mendelian ratios, above 25 % for WT, BACHD, and KO groups, and above 50% for HET and 
BACHD-HET groups, we were surprised to have only 12 individuals in the BACHD-KO 
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group that corresponded to only 10% of total offspring. Currently, association with embryonic 
development or birth defects has not been reported for BACHD or the KO mice, and our 
numbers confirm this information. However, in our studies, the synergistic cross combination 
of BACHD with KO mice αBc/HspB2 resulted in fewer animals and therefore this genetic 
combination may have affected embryonic development or birth of these mice.  
 
5.3.2. αBc/HspB2 deficiency does not impair behavioral deficits in BACHD mice 
 
After noticing an abnormal genotype distribution in our mice cohort, we premised that 
αBc/HspB2 deficiency would worsen and accelerate the BACHD deficits. To confirm αBc 
was efficiently deleted, we performed QPCR to evaluate αBc in our mice cohort (Fig. 1A). It 
was demonstrated that the BACHD mice showed behavioral changes as early as 2-3 months 
of age (27, 28). Since the mice deficient for αBc/HspB2 showed debilitating phenotypes about 
9-10 months of age (24, 26), we decided to investigate the behavioral phenotypes of our mice 
groups (above described) at 3, 7, 10, 13 months of age corresponding to early-, mid- and late-
stages of the disease, respectively. The rotarod and balance beam assays are tests of motor 
coordination, while the open field test affords insight into general activity levels and anxiety 
related behavior. These tests were designed to examine the effect αBc/HspB2 deficiency on 
motor and coordination defects in BACHD mice. 
Rotarod performance is a sensitive indicator of balance and motor coordination, which 
has been repeatedly shown to decline in mouse models of HD. 
During testing for each time, latency to fall from the apparatus was measured, and we 
observed as in Chapter 3, and impairment of motor coordination performing the test in the 
BACHD mice. This behavioral deficit in BACHD was consistently significant from early to 
late stage of the disease, 3 month to 13 months, respectively (Fig. 1B). Unexpectedly, deletion 
of αBc/HspB2 on the KO mice ameliorated their rotarod performance when compared to WT 
mice, from 3 to 13 months of age. The same effect was observed on the combined HD 
transgene and chaperone deficiency group of mice, BACHD-KO, in which deletion 
αBc/HspB2 was shown to improve motor ability in the rotarod in the BACHD mice, 
especially at 13 months of age (Fig. 1B). 
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Balance Beam is commonly used to test refined balance and motor tasks. Time to 
cross the beam was also evaluated in this group of mice. Consistent with previous results, we 
could find a BACHD phenotype on the time to cross the beam, being significant after the 10 
months time point (Fig. 1C). Genetic deletion of αBc/HspB2 did not worsen the BACHD 
phenotype at any time point (Fig. 1C) and similar to what we found on the Rotarod, at 13 
months of age it showed a tendency to improve time to cross the beam on the BACHD-KO 
group (Fig. 1C).   
Open field test is one of the most common tests to monitor general motor activity, 
exploratory behavior and elevated plus maze measures of anxiety (29, 30). Normal behavior 
in mice is to seek the protection of the periphery rather than the vulnerability of the center in 
the open field, and to stay longer periods in the closed arms in the elevated plus maze. Mice 
were individually placed in an open arena equipped with infrared photobeams to monitor mice 
behavior for 15 minutes without the experimenter being present in the room. First of all, WT 
and KO groups behaved similarly in terms of rearing (data not shown), and total movement 
indicating that loss of αBc/HspB2 alone had negligible effect on locomotion at this age group 
(Fig 1D). Age associated muscle degeneration reported in the KO mice was not manifested in 
terms of locomotion defects at this age group as all parameters counts of KO group of animals 
was comparable to WT. Similarly, the BACHD group was comparable to WT suggesting that 
the expression of mutant mHtt in mice did not significantly affect locomotion by itself during 
Open Field (Fig. 1D) and it did not affect anxiety levels in the elevated plus maze (data not 
shown). When the BACHD transgene expression was combined with αBc/HspB2 deficiency 
in the BACHD-KO group, the effect did not worsen the behavioral activity of the BACHD or 
the KO groups in total activity (Fig 1D). 
As expected, we observed that BACHD and BACHD-HET and BACHD-KO mice 
gain significantly more weight (an average of 20–30%) than their littermate’s controls, 
between 3 and 7 months until 13 months of age (Fig. 1E). However, after 9-10 months of age, 
when αBc/HspB2 deficient mice (KO) has been indicated to have a more robust phenotype, 
we observe a strong weight loss on the BACHD-KO mice, suggesting that chaperone 
deficiency may play a role at metabolic functions in BACHD mice. Since weight can affect 
motor performance, we examined the relationship of weight and rotarod and balance beam 
performance in BACHD mice. We found that the rotarod and balance beam performance in 
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this cohort of BACHD and BACHD-KO mice at 7, 10 and 13 months was significantly 
correlated with body weight (Fig 1G). Therefore, the improvement seen in the KO when 
compared to WT (Fig 1F) and in BACHD-KO when compared to BACHD may be explained 
by weight differences or the effect of weight on motor performance. Thus, we conclude that 
αBc/HspB2 deletion affects BACHD motor performance by altering their body weight and 
most likely metabolic functions. 
These results suggest a stronger implication of body weight on motor behavioral 
analyses and the need to perform correlation analyses during the performance of these tests. 
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Figure 1. αBc/HspB2 genetic deletion does not influence behavioral phenotypes in BACHD mice. 
Behavioral readouts of disease progression were measured at 3, 7, 10 and 13 months of age using 
rotarod, balance beam and open fieldtesting. Data at each time point were tested for statistically 
significant differences using two-way ANOVA followed by Tukey post-hoc tests. At 3 months of age, 
group sizes were as follows WT (n=20), HET (n=20), KO (n=27) BACHD (n=20), BACHD-HET 
(n=20), and BACHD-KO (n=12). Error bars represent SD. * = p <0.05 or **= <0.01 for main p effect 
of the BACHD by two-way ANOVA.  
A) αBc mRNA protein levels in brains from 3 month old mice. As expected, we could verify 
downregulation of αBc (CRYAB gene) in brain from αBc /HspB2−/− mice. B) Rotarod. BACHD mice 
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fall off an accelerating rotarod sooner than WT littermates, but this is surprisingly not aggravated by 
αBc KO genotype. Instead, KO mice perform significantly better than WT at rotarod at every time 
point. The BACHD-KO group also performs better than the BACHD group at 13 months. C) Balance 
Beam. BACHD mice are slower to cross an elevated balance beam than WT littermates at 13 months 
of age, but this is not affected by αBc KO genotype (no significant effect of αBc KO genotype at any 
age) and there is no significant interaction between the two factors. D) Open field. BACHD do not 
present a phenotype on the open field movement evaluation when compared to WT littermates, and 
there is no additional effect by αBc KO genotype (no significant effect of αBc KO genotype at any 
age). E) Body Weight BACHD. KO genotype does not influence WT body weight, but it does 
significantly impact BACHD body weight after the 10 to 13 month time points. The correlation 
between body weight and rotarod and balance beam performance in BACHD (n=20) and BACHD-KO 
mice (n=12) was examined. Correlations graphs with comparisons for WT and KO and for BACHD 
and BACHD-KO. F) Body weight correlation with latency to fall in rotarod at 13 months, WT and KO 
were significantly different, G) Body weight correlation with latency to fall in rotarod at 13 months, 
BACHD and BACHD-KO were significantly different. 
Our data indicate that the rotarod and balance beam BACHD and BACHD-KO mice motor 
performance is correlated with their body weight loss at 7, 10 and months. Therefore, the improvement 
seen in the KO compared to WT mice, and BACHD-KO compared to the BACHD may be explained 
by weight differences or the effect of weight on motor performance. Data were analyzed by using the 
nonparametric Spearman correlation coefficient. 
 
5.3.3.  αBc/HspB2 deficiency does not alter HD related genes  
 
Despite finding a that αBc/HspB2 deficiency was responsible to decrease the BACHD 
body weight phenotype, especially after 10 months, we wanted to confirm that besides 
playing a role on metabolic functions in the BACHD mice, we could study whether this 
chaperone genetic ablation, could be related to any HD related genes. We repeated the same 
procedure described above in Chapter 3, and looked at known and well established HD genes. 
We used QPCR to quantify mRNA levels of some genes in brains from 13-month-old KO 
mice. We did not find any alteration caused by αBc/HspB2 deficiency in common HD genes 
as DARPP-32, Dopamine receptors, other sHsps (Hsp70, Hsp27, and Hsp90), caspase-3 and 
p53. Unfortunetaly, we did not analyze any potential HD associated-metabolic markers in our 
study. However based on our results here, we hypothesized that αBc/HspB2 deletion may 
play an important role in metabolic function overall. Studying αBc/HspB2 genetic ablation in 
	  	   105	  
lipid and bone markers, glucose homeostasis, peripheral hormones that are know to affect 
energy homeostasis in Huntington’s disease (31), could be a useful approach to study HD 
metabolic impairment and its modulation by sHsps. 
 
5.4. Discussion 
Here, we performed an extensive study of the effect of the small Hsps αBc/HspB2 
genetic deletion on the BACHD mouse model. We focused on behavioral and motor analyses, 
including rotarod, balance beam and open field. In contrast to many previous studies, our 
results did not show aggravated BACHD motor deficits by the knocking down αBc/HspB2. 
Unexpectedly, we observed that αBc/HspB2 deficient mice (KO) could have a better motor 
performance on rotarod due to a direct effect on BACHD weight loss. Alternatively, the 
failure of two sHsps genetic deletion to be detrimental in the context of HD could reflect the 
requirement for a finely balanced concerted action of several chaperone systems, along with 
the ability to up- or down-regulate their levels in response to specific cellular requirements. A 
better strategy might be to target the regulators of the stress-induced chaperone response, 
thereby coordinately inducing many chaperones with distinct and complimentary 
cytoprotective functions. Together with our results from Chapter 3, we hypothesize that 
constitutive or transient overexpression of individual sHsps may be more successful in 
ameliorating disease phenotypes. Although, all Hsps have many cellular functions and when 
chronically deleted or overexpressed, may have deleterious as well as beneficial consequences 
and cause the protein networks to further adjust to neutralize potentially damaging. It is 
possible that αBc/HspB2 deficiency alters disease progression in other studies and other 
disease like its has been shown in AD (32) but not in ours because αBc/HspB2 deficiency has 
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multiple positive and negative effects that offset each other in BACHD mice. Further studies 
will be needed to address how to modulate the chaperone network in order to alleviate the 
devastating symptoms of HD and other neurological disorders. Regardless of the mechanisms 
governing expression and modulation of sHsp activity, the discrepancy between large scale 
upregulation in HD patients of certain genes and biomarkers and few alterations in the 
BACHD mice system highlights the need to use multiple animal models of disease in order to 
explore disease mechanisms. Here, we have shown that removing αBc/HspB2 does not 
worsen disease-associated behavioral changes in the full-length HD mouse model - BACHD. 
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6. General Discussion and Conclusions  
 
Huntington’s disease (HD) is a fatal, devastating and progressive 
neurodegenerative disorder for which only minor symptomatic treatments are available. 
A better understanding of the pathology, and identification of biomarkers will facilitate 
the development of disease-modifying treatments. HD is, in principal, a privilledged 
model disease for development of biomarkers because it is an autosomal-dominant 
disease with complete penetrance, caused by a single gene mutation, in which the 
neurodegenerative process can be assessed many years before onset of signs and 
symptoms of manifest disease. Therefore, approaches that target molecular chaperones 
may be beneficial in protein misfolding diseases. 
In Chapter 3, we report for the first time the effect of the sHsp αBc in a full-length 
mHtt model, the BACHD mouse. Expression of αBc in astrocytes improved the motor 
(Rotarod and Balance Beam) and cognitive performance (Water-T-maze) of the BACHD 
mice, as well as neuropathological features associated with HD. Overall, our data indicate 
that modulating the levels of αBc protect against the progression of HD. Taken into 
account our results, the most obvious candidate mechanism for chaperone-mediated 
rescue of HD neurotoxicity is inhibiting or reversing htt aggregate (fibrils/polymers) 
formation. Although mHtt is expressed in glial cells, it is primarily in neuronal cells that 
Htt inclusions are found (1, 2). Our results indicate that αBc modulates mhtt levels and 
the features of IBs in a typical chaperone manner. Interestingly, however, the effect of 
this chaperone is via overexpressing αBc in astrocytes. Overexpression of chaperones 
may reduce large IBs by preventing oligomer formation, and oligomeric precursors may 
be the most toxic species to the cell (3–5). As with most Hsps, sHps can also be 
important for protein stability and protein turnover. Evidence suggests that affinity of 
αBc for its chaperone substrates is modulated by its chaperone oligomerization status and 
the functional structure of αBc is a dimer, which results from interactions of β-strands in 
the α-crystallin domain (6, 7). Since the binding capacity can reach one substrate protein 
per sHsp subunit, big chaperone oligomer structures (via sHsp oligomerized complexes) 
are major contributors to the chaperoning capacity of the cell. It remains unclear how the 
decision to refold or degrade a misfolded protein is made. Some sHsps (αBc and Hsp27) 
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interact directly or indirectly with the proteasome and form part of ubiquitin ligase 
complexes (αBc and HspB10) that are involved in the proteasomal degradation of certain 
proteins in a quite selective manner under stress conditions (8). Thus, αBc could regulate 
mHtt protein levels by stabilizing mHtt in IBs or by promoting misfolded mhtt refolding 
with the cooperative help of other chaperone complexes, namely the Hsp70/Hsp40 
machinery, as well as targeting it for proteosomal degradation. 
 
 
Figure 1. A model for chaperone-mediated suppression of neurotoxicity. Fibril formation is a 
multi step process involving a number of intermediate structures that are thought to mediate 
neurotoxicity. Chaperone proteins may prevent neurotoxicity by preventing the conversion of 
native proteins to abnormal toxic conformations (A), by preventing the formation of pre-fibrillar 
intermediates (B), by preventing the conversion to mature fibrils (C), and/or by facilitating the 
conversion of toxic intermediates to non-toxic amorphous aggregates (D). (4) 
 
 We hypothesize that αBc has an important modulatory role in HD since the 
ability to effectively initiate the heat shock response, and other homeostatic cellular 
pathways (e.g., apoptosis, oxidative stress) in which αBc functions, are compromised 
during HD disease progression (9). We should also take into account, as a chaperone with 
multi-functional capabilities, αBc may alleviate stress by promoting the proteasomal 
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degradation of corrupt proteins (10, 11), by stabilizing intermediate filaments and the 
cytoskeleton integrity (12, 13) or preventing apoptosis (14–17). In Chapter 4 we tested 
the hypothesis that BACHD astrocytes have a reduced antioxidant potential leading to an 
increased oxidative stress in neurons, and overexpression of αBc can rescue this effect 
and protect neurons from those deleterious effects. Our data shows a trend towards an 
increase of caspase-3 activity and protein carbonyl groups in primary cell cultures of 
BACHD. Oxidative stress is mediated by increases in ROS including superoxide (O2-), 
hydrogen peroxide (H2O2), hydroxyl radical (OH-), and reactive nitrogen species such as 
peroxynitrite (ONOO-) (18). Indeed, we provided evidence that αBc overexpression 
could protect astrocytes from H2O2 –induced oxidative stress is increased. Mitochondria 
dysfunction may be a source of ROS overproduction in neurons and it is a common 
feature found in HD (19, 20). By directly binding to procaspase-3, αBc inhibits the pro-
apoptotic proteins, bcl-X(S), Bax and p53 by preventing their translocations from cytosol 
into mitochondria during apoptosis (15, 21). However, we failed to detect these effects in 
p53 and caspase-3 expression and activity in our BACHD mouse brains (Chapter 4 – 
Table 1).  
Evidence of enhanced oxidative stress in HD brains includes an accumulation of 
lipofuscin, 8-OH-dG, and carbonyl formation (22). However, although oxidative damage 
is well described in HD, little is known about the specific protein targets of this damage. 
The major carbonylated proteins in both striatum and cortex from human HD samples are 
those involved in mitochondrial energy pathways and glucose metabolism in accordance 
with the impaired energy metabolism described in HD. Despite not testing for expression 
of 8-OH-dG in our mice model, we did observe a trend for levels of carbonylation in our 
BACHD mice, but αBc overexpression did not significantly rescue this effect.  
We also observed in general that the large-scale upregulation of HD-related genes 
that is observed in human HD brains is not paralleled in late-stage BACHD brains. 
Regardless of the mechanisms governing the protective effects of αBc expression, the 
discrepancy between large scale complement upregulation in HD patients and few 
alterations in the complement system in BACHD mice highlights the need to use multiple 
animal models of disease in order to explore disease mechanisms. Specifically, future 
studies of the sHsps overexpression in HD should consider other animal models besides 
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the BACHD mouse model in the hope that they more accurately reflect the status of 
human HD patients. 
Although our data do not establish a mechanism by which overexpression of  αBc 
in astrocytes is likely to play a critical function in the modulation of mHtt and oxidative 
stress in the context of BACHD mice, these findings open up new avenues in the 
investigation of Hsps over-expression in astrocytes and their potential protective role in 
neurons through a non-cell autonomous manner in HD and other proteinopathies. 
In Chapter 5, we tested the impact of αBc deletion in the BACHD mice model. 
An enormous caveat to this study using the αBc deficient mice: these mice also lack the 
sHsp HspB2 due to their promoter proximity (23). HspB2 is not thought to be  inducible, 
so the levels of HspB2 are typically not elevated in neurological disorders (7). Mice 
lacking both αBc and HspB2 showed a decrease of the BACHD body weight phenotype, 
confirming the role of sHsps in metabolic changes as previously discussed. The decrease 
on body weight was correlated with better performance in our behavior paradigms such 
as rotarod and balance beam. Though, αBc/HspB2 mice have worse disease (24), which 
supports the idea that sHsps are serving protective roles whether that is due to αBc or 
HspB2. An additional point to consider is whether the phenotype observed in αBc/HspB2 
deficient mice is due to the lack of the sHSPs or the altered levels of another molecule 
that is dependent on normal sHsp function. If isogenic mouse strains are not used as 
controls, then it is possible that polymorphisms in other genes could be the cause of 
differences seen between the WT and αBc/HspB2 deficient mice. 
How sHsps , especially αBc, are neuroprotective is still a subject of debate.  
 
6.1.  Non–cell autonomous pathology in HD 
Growing evidence shows that HD and other neurodegenerative diseases (ALS, 
AD, PD)  result from the convergence of damage developed within multiple cell types, 
including within neighboring non-neuronal supporting cells, which is crucial to neuronal 
dysfunction. 
We have analysed αBc expression in astrocytes, but we did not test these 
conditions in other glial cells, namely oligodendrocytes, that are also known to express 
sHsps (7, 25) and to contribute to in HD progression (26). In fact,  previous MRI studies 
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have detected abnormalities in both gray and white matter starting in premanifest stages 
of HD (27). Recently, structural and molecular myelination deficits were found to occur 
prior to neuronal loss in the YAC128 and BACHD (29) and knock-in (28) models of 
HD. These findings indicate that white matter deficits in HD are an early phenotype 
associated with cell-intrinsic effects of mHtt on myelin-related transcripts in 
oligodendrocytes, and raise the possibility that white matter abnormalities may be an 
early contributing factor to the pathogenesis of HD. Thus, testing in vitro and in vivo 
overexpression of sHsps in oligodendrocytes could provide novel potential therapeutic 
targets for HD and other neurodegenerative diseases. 
 
6.2. Prion-like spreading of mHtt pathology in HD 
 
Several reports have provided evidence that large Htt-containing inclusions are 
not correlated with cytotoxicity (30) and might even be protective (3). However, as 
discussed above, many aggregated precursors to inclusions are present, including 
individual oligomeric and amyloid fibrils, that are too small to be visualized by light 
microscopy and that were therefore undetectable in many of these studies, including ours. 
Although tracking the various oligomeric and aggregated forms of Htt that are below the 
size of an inclusion in either mouse models or patients in vivo is not possible at the 
present time, the observation of inclusions in a specific cell type provides evidence that 
self-association has progressed through a series of smaller aggregated species to an 
amyloid fibril end point (31, 32). Inclusions form in a wide range of peripheral tissues in 
mouse models that carry highly expanded CAG repeats (33). These inclusions occur 
predominantly in cells that have entered mitotic arrest, which suggests that cell division 
acts to delay the pathogenetic process. The acceleration of aggregation through seeding 
suggests the possibility of a prion-like mechanism of cell-to-cell transmission (34) and 
trans-neuronal propagation of mHtt might be an important and underestimated 
contributor to the pathophysiology of HD. Interestingly, αBc is secreted in exosomes 
under a variety of stress-related conditions (35). One possible mechanism of modulating 
neuronal IBs and its percursor species could be through αBc-mediated extracellular 
signaling from astrocytes to neurons. 
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There is emerging evidence that astrocyte-derived exosomes carry 
neuroprotective cargo and could contribute to neuronal survival (36). Exosomes may 
execute their functions by distinct modes of action: (1) internalization by target cells and 
cargo retrieval, (2) binding to the cell surface and triggering second messenger pathways, 
and (3) release of components into the extracellular matrix. However, their interaction as 
well as their protein content with target cells is not well understood at a mechanistic level 
(36). A study using retinal pigment epithelial (RPE) cells (37) showed that an increased 
uptake of exogenous αBc and protection from oxidative stress and apoptosis by inhibition 
of caspase-3 and PARP activation were observed in stressed RPE cultures. In this 
manner, we speculate that exosomes containing αBc could protect both glia and neuronal 
population in BACHD from mhtt-derived toxicity, as activation of caspase-3 and 
oxidative stress. Future and critical experiments need to be designed to address the extent 
to which secreted αBc may modulates mHtt prion-like aggregate propagation and its 
contribution to disease progression in HD.  
 
6.3. Final Remarks 
 
The results obtained in this thesis, provide several insights into the complex role 
of the pleiotropic sHsp, αBc, in HD-related mechanisms and also other neurodegenerative 
disorders. Although there are currently no effective disease-modifying therapies, 
therapeutic strategies involving overexpression of chaperones and other protein quality 
control mechanisms are under investigation. Therefore, our study will help to open new 
research venues, crucial for obtaining a more comprehensive level of understanding the 
interplay between Hsps and their multiple functions on neurological disorders. 
Ultimately, the knowledge reported here will help targetting important molecules, cellular 
mechanisms and pathways for therapeutic intervention in HD and in other diseases of 
protein misfolding. 
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7.1.  αB-crystallin overexpression does not increase life span in the R6/2 
mouse model of Huntington’s disease 
 
The early onset of behavioral symptoms, robust and severe HD-like phenotypes 
and brain neurodegeneration make the exon-1 fragment model R6/2 mice an attractive 
model for the study of presymptomatic therapies. During the time of my PhD project, I 
have tried to test in parallel the overexpression of αBc in the modulation of the disease in 
both full-length mHtt model – BACHD and in the exon-1 fragment model R6/2 mice of 
HD, to have be able to expect robust results in two distinct HD models for the distinct 
behavioral paradigms. However, the R6/2 mice breeding results were more difficult than 
expected, and even using ovarian-transplanted R6/2 mice, my ratios of the 4 genotypes 
were very low to perform behavioral analyses. Therefore, with the single good cohort I 
could obtain from R6/2 and Cryab Tg mice crossing towards the end of my studies, I have 
decided to perform survival analyses to test the potential protective rescue effect of αBc 
overexpression in the severe and short life-span of the R6/2 mice (Figure A1). 
 
 
 
 
Figure A1. αB-crystallin 
overexpression does not 
increase life span in the 
R6/2 mouse model of 
Huntington’s disease 
Kaplan-Meier survival curve 
for the indicated genotypes 
WT (n=24), Cryab Tg 
(n=26), R6/2 (n=18), DTg 
(n=21), demonstrates that the 
astrocytic overexpression of 
αBc does not significantly 
impact the survival of R6/2 
mice (log rank Mantel-Cox 
test: p = 0.2893) 
 
 
αBc astrocytic overexpression does not increase life span in the R6/2 mouse model 
of Huntington’s disease. The Cryab Tg did not change the WT phenotype - normal life -
span, thus both WT and Cryab Tg Despite the fact of observing encouraging results in the 
initial phase, where R6/2 start dying earlier (83-84 days) than the DTg littermates that 
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started 20 days later (106-108 days) (Fig. A1), the Kaplan-Meier survival curves were not 
significantly different between R6/2 and DTg, according to the of Mantel-Cox test (Fig. 
A1).  
We concluded then, that despite the R6/2 model being an extremely attractive 
model for therapeutic targets’ testing, to be able to study the progression of HD disease 
and to evaluate modest but significant improvement of astrocytic αBc, this model may be 
to severe, and therefore the full-length BACHD model was more suitable for our aims 
during this PhD project. 
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